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Abstract 
Tobacco harm reduction involves strategies designed to reduce the harms associated with 
tobacco use, for example by cutting down cigarette consumption and thereby reducing 
exposure to the risks associated with smoking. In addition to potentially reducing the harms 
of continued smoking, there is evidence that some harm reduction strategies are positively 
associated with quitting smoking entirely. A variety of interventions exist that can be used to 
aid both cessation and smoking reduction. However, there are limitations with using current 
treatments, with most attempts to change smoking behaviour ultimately ending with relapse. 
Numerous limitations of current treatments have been noted in the past, including that 
existing nicotine replacement products may not provide sufficient nicotine, and / or that the 
time course of nicotine delivery may not be optimal for promoting reduction. The broad 
objective of this thesis is to understand how smoking reduction influences smoking 
behaviours and cessation outcomes as well as smoking-related harm exposure.  
To achieve this aim, firstly, knowing the content of nicotine in supplementary 
products can help with interpreting the outcomes of clinical trials and with improving product 
design. Vaporised nicotine products (VNPs) – commonly known as electronic cigarettes – are 
increasingly being used by smokers to reduce their smoking, and there is some evidence that 
they can be effective cessation aids. A key issue with testing the effectiveness of these 
products, however, as been quantifying the variability in the amount of nicotine contained in 
products. As such, an assay was developed and applied to determine the nicotine content in 
one brand of VNPs which consisted of a fibrous pad in the cartridge. In addition to finding 
substantial variation between product batches, we also found that the measured nicotine 
content in the cartridge was lower than the stated content on the product label. The accurate 
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determination of the quantity of nicotine in VNPs has important implications for both 
consumer safety and the further study of these devices. 
Secondly, smoking reduction is not only a reduction in the number of smoked 
cigarettes, but also an expected reduction in exposure of smoking-related harm. Biological 
markers can be used to indicate the intake of nicotine and smoking-related harm. 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is a metabolite of 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which is a tobacco specific carcinogen. 
As such, NNAL is considered a biological marker associated with tobacco-related harm. To 
measure the levels of NNAL in smokers’ urine, solid phase extraction (SPE) assay has been 
used in previously reported studies. However, the sample preparation procedures required 
with these SPE assays are complicated and time consuming, limiting their use. A simple and 
efficient liquid-liquid extraction assay combined with ultra-performance liquid 
chromatography with tandem mass spectrometry (UPLC-MS/MS) was designed in this study, 
and applied to the smokers’ urine to measure changes in harm exposure over the course of a 
quit attempt. As expected, the NNAL levels were significantly decreased following the quit 
attempt. This supports the use of NNAL as a biomarker of tobacco-related harm exposure and 
harm minimisation. This assay is an improvement over existing SPE-based methods in that it 
is substantially less complicated while maintaining adequate sensitivity and is a 
straightforward approach to measuring NNAL levels. The assay also demonstrated that using 
enzymatic hydrolysis approach of NNAL-glucuronide – had taken by other studies – as a 
technique for measuring the aglycone was clearly unreliable. There was a potential for 
significant loss of either free NNAL and NNAL aglycone. NNAL-glucuronide standards are 
recommended to utilise for proper validation of indirect methods such as enzymatic 
hydrolysis approach to measure total NNAL (free + glucuronide). 
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Finally, we explored the mechanism through which two medications – specifically 
varenicline and nicotine patch – promote reduction. There has been growing research interest 
in using nicotine replacement medications to aid smoking reduction prior to a quit attempt. 
Gaining a better understanding of how treatments influence smoking reduction may allow for 
better tailoring of treatments and, ultimately, better cessation outcomes. The objective of the 
study was to test the effects of the pre-quit use of varenicline and nicotine patch on smoking 
rate and satisfaction with smoking. Participants in the two pre-quit treatment groups reported 
significant reductions in both their satisfaction with smoking and smoking rate from baseline 
to the end of pre-quit period; participants in the standard patch group, which started to use of 
nicotine patch at a quit attempt day, did not. The observed reduction of smoking rate was 
associated with the satisfaction with smoking, although the mediation effect of satisfaction 
was weak. As such, monitoring reductions in satisfaction does not appear to be a viable 
method of evaluating responsiveness to treatment and, or for tailoring. 
In summary, this research developed a sensitive and efficient assay to determine 
nicotine content in supplementary nicotine products, providing valuable data for further 
research on these products. Furthermore, an assay for determination of NNAL levels in 
smokers’ urine was developed, which was applied to determine the reduction of smoking-
related harm exposure in a smoking cessation study. Finally, this research demonstrated that 
pre-quit treatment use led to reductions in satisfaction with smoking and the smoking rate, 
and the satisfaction was associated with the reduction in smoking rate. Monitoring such 
reductions may prove to be useful in evaluating responsiveness to treatment, risk of harm, 
and allow for tailoring of treatment.  
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Chapter 1: Introduction 
Chapter 1
2	
Cigarette smoking remains one of the greatest causes of preventable death and disease in the 
developed world [1]. The most obvious solution to this problem is complete cessation from 
tobacco product use. However, despite years of attention from the public health community, 
rates of smoking remain unacceptably high; this is not only true in the developing world [2], 
but also in developed countries, where smoking rates remain high, especially among 
vulnerable pockets of the community (e.g., those with mental health issues [3, 4]).   
The recalcitrant nature of smoking has led many in the tobacco control community to 
entertain the virtues of harm reduction strategies. Harm reduction can be defined as a policy, 
strategy or specific intervention to minimise the adverse consequences associated with the 
continuing drug use [5]. Tobacco harm reduction typically involves cutting down – but not 
necessarily completely stopping – the consumption of traditional combustible cigarettes, 
thereby reducing exposure to the risks associated with smoking. Reduction can theoretically 
be accomplished through restraint strategies (e.g., willpower) alone, but sustained reduction 
has proved difficult to maintain, presumably because of dependence on nicotine. An alternate 
strategy is to replace, or substitute, the nicotine forgone through reduction via another source, 
for example using nicotine replacement products such as nicotine gum or nicotine lozenges [6, 
7]. More recently, researchers have explored the potential impact of alternate additional 
nicotine delivery systems, most notably vaporised nicotine products (VNPs), colloquially 
referred to as electronic-cigarettes (or ‘e-cigarettes’). Regardless of the method of reduction 
used, however, the goal remains the same: to reduce the consumption of traditional 
combustible cigarettes, thereby reducing tobacco-related harm.  
While it seems self-evident that smoking fewer cigarettes would be better than 
smoking more, quantifying the risks and benefits of tobacco harm reduction, either at a 
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socially or an individual level, is complicated. Firstly, there is no known safe level of 
smoking: every cigarette smoked increases an individual’s risk of tobacco-related disease [8, 
9]. Furthermore, even assessing reduction itself is complicated as the exact harm associated 
with each cigarette is not consistent: smokers can compensate for reduction by smoking each 
remaining cigarette more intensely; thus, simply counting the number of cigarettes per day 
(CPD) that an individual consumes is a crude measure reduction, let alone harm reduction.  
 
To better quantify reduction, tobacco researchers have turned to biological markers of 
tobacco exposure. Biological markers can be used to measure nicotine and its metabolites in 
biological fluids, thereby assessing exposure to tobacco products. Similarly, researchers have 
developed methods for assessing the constituents of products themselves [10] as a method of 
measuring intake and exposure. A variety of assays currently exist for the measurement of 
both biological markers of tobacco exposure and the constituents of tobacco products. These 
assays have been used by researchers to access smoking and nicotine intake. However, no 
current measure is a perfect proxy for actual exposure and existing measures have known 
limitations. The objective of this thesis was to develop improved measures of exposure – both 
in terms of measuring biological markers of actual exposure, and in terms of the constituents 
of products themselves – and to use these measures to studying smoking behaviour and its 
consequences.  
 
The whole thesis is divided into eight chapters.  Chapter 2 of the thesis is a literature 
review covering key topics including: smoking prevalence and smoking related harm; 
tobacco harm reduction; and current methods of accomplishing reduction used in harm 
reduction and their limitations.  
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With the high interest in tobacco harm reduction, a variety of medical nicotine 
products are utilised to assist harm reduction. However, if the nicotine content in the products 
is unknown or inconsistent, it is difficult to confidently say that the products can be useful in 
assessing smoking reduction. This is particularly important given that VNPs are unregulated 
and produced with unknown manufacturing standards [11]. With this concern in mind, 
Chapter 3 of this thesis includes the development of an assay to determine the nicotine 
content in VNP products, and the application of this assay on VNP products to investigate 
whether the nicotine content is consistent with the label and consistent between product 
batches (Study 1). Knowing the nicotine content would allow better interpretation of clinical 
outcomes when using these products in smoking reduction studies. 
 
To assess the success of the harm reduction, simply measuring the number of 
cigarettes smoked is not sufficient. Smokers can titrate the amount of nicotine that they 
extract from individual cigarettes; thus, they can compensate for skipped cigarettes by 
smoking the remaining cigarettes more intensely, potentially obviating any possible benefits 
of reduced intake. To overcome this issue, biological markers can be used to accurately 
assess exposure and nicotine intake. Nicotine is extensively metabolised by a variety of liver 
enzymes. Cytochrome P450 2A6 is one of the main nicotine metabolising enzyme in humans. 
Nicotine and its metabolites are further metabolised through glucuronidation process, which 
is facilitated by uridine 5’-diphospho-glucuronosyltransferase. Nicotine also forms other 
chemicals during curing process. Tobacco-specific nitrosamines (TSNAs) are one group of 
carcinogens in tobacco products, and are also presented in tobacco smoke. 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-1butanone (NNK), N’-nitrosonornicotine (NNN), N’-
nitrosoanabasine (NAB), and N’-nitrosoanatabine (NAT) are formed by oxidation and 
nitrosation of nicotine. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is the major 
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metabolite of NNK, which is formed from nicotine and related compounds by a nitrosation 
reaction that occurs during the curing of tobacco. Total NNAL (free + glucuronide) is not 
presented in cigarette smoke, therefore it is considered an effective biomarker of NNK uptake 
and hence tobacco exposure. The long biologic half-life of NNAL also can be used to 
determine the exposure of tobacco-related harm. As detailed in Chapter 4, current methods 
for measuring NNAL levels involve complex sample preparation procedures. An easy but 
effective assay is required to measure NNAL levels in smokers’ urine. Chapter 4 of this thesis 
contains the development of an assay for determining NNAL levels in human urine (Study 2), 
and Chapter 5 of this thesis contains the application of this NNAL assay to smokers’ urine 
that had been collected from a smoking cessation study (Study 3). 
 
Smoking reduction, as well as being seen as a potentially beneficial end in and of 
itself, research also suggests that it may promote complete cessation. In the final data chapter 
(Chapter 6) of the thesis I attempt to gain a better understanding of the impact of reduction 
using data drawn from a clinical trial involving two treatments, nicotine patches and 
varenicline (Study 4). The purpose of the trial was to examine the effects of pre-quit, or pre-
cessation, treatment on daily smoking rate and satisfaction with smoking, and test the 
relationship between these variables during the two weeks leading up to a quit attempt. 
Ecological momentary assessment (EMA) was used to monitor the smoking behaviour, affect 
and activities in real-time.  
 
The final two chapters of this thesis focus on a general discussion and conclusion of 
the developed assays for determining smoking harm reduction: the determination of nicotine 
in substitute products, and biological markers of actual smoking harm exposure. These 
measures assist the study of smoking behaviour and its consequences. 
	
 
 
 
 
 
 
Chapter 2: Literature Review 
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2.1 Background 
Each year, approximately five million people worldwide die from direct tobacco use and 
600,000 non-smokers die from exposure to second-hand smoke [1]. Tobacco smoking is a 
leading risk factor for tobacco-related chronic diseases, including respiratory disease, 
cardiovascular disease and different types of cancers, especially lung cancer [9]. More than 
80% of the chronic lung diseases, including respiratory infections, poor lung compliance, 
chronic obstructive pulmonary disease (COPD) and worsening of asthma, are attributed to 
smoking [12]. Indeed, tobacco smoking is the most important risk factor for COPD [13]. 
Tobacco-related COPD is the fourth most common cause of chronic disability and death in 
developed countries. Exposure to second-hand smoke is also a risk factor for respiratory 
diseases in children and adults who do not smoke. Long-term exposure to second-hand smoke 
can increase lung cancer risk by up to 30% and coronary heart disease in non-smoking adults 
[14, 15].  
 
Quitting smoking is the most effective intervention for current smokers to reduce 
morbidity and mortality of smoking-related diseases. For instance, studies found that 
smoking cessation reduced 36% of mortality risk in patient with coronary heart disease [16] 
and significantly improved an individual’s prognosis after a cardiac event [17]. With COPD, 
smoking cessation is considered as an effective treatment for reducing the progression of this 
disease [18, 19]. A long-term follow-up study also indicated that quitting smoking was 
associated with a slower lung function decline compared with continuing smokers [20]. 
Smoking cessation also reduces COPD mortality risk ranging from 32-84% compared with 
continuing smokers [21]. The majority of smokers would like to stop smoking, thereby 
reducing their personal risk of developing smoking-related diseases [8, 9]. More than half of 
US smokers have tried to quit smoking. Similarly, in Australia, approximately 75% of 
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smokers have tried to change smoking behaviour in the last 12 months [22]. Previous studies 
have also indicated that about 40% of smokers made quit attempts in a given year [23], and 
the quit attempt lasted for a short or long-term period of time [24, 25]. Even though many 
smokers make quit attempts every year, most of these quit attempts ultimately fail. To reduce 
smoking rates and reduce smoking-related harm, researchers and policy makers have 
increased their interest in exploring tobacco harm reduction strategies. 
 
2.2 Tobacco harm reduction  
Nicotine is considered to be the primary addictive component driving the consumption of 
tobacco, yet the majority of smoking-related harm themselves are not caused by nicotine 
itself [26]. When burning tobacco, the smoke contains an extraordinarily complicated mixture, 
which includes over 60 known carcinogens. Tobacco smoke exposure is the major risk of 
causing cancer, heart disease, respiratory disease and other deadly consequences [27]. 
Considering the tobacco-related morbidity and mortality, tobacco control and promotion of 
public health are an important part of the global health strategy [28]. Harm reduction can be 
defined as a policy, strategy or specific intervention to minimise the adverse consequences 
associated with continuing drug use [5]. Tobacco harm reduction involves cutting down the 
consumption of traditional combustible cigarette but not necessarily completely stopping 
nicotine use, thereby reducing exposure to the risks associated with smoking [27]. As well as 
potentially reducing the harms associated with smoking, reducing the number of cigarettes 
smoked per day may also prompt quitting itself [29, 30]. In other words, harm reduction 
approaches may result in increased motivation to quit completely [31-35].  
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2.2.1 Tobacco control strategies 
In Australia, governments work in collaboration with non-government agencies to conduct 
tobacco control strategies designed to reduce tobacco use [36]; the same is true in other 
countries [1]. One of the effective tobacco control strategies is increasing tobacco product 
taxation. Studies have shown about 44% of smokers changed their smoking behaviour due to 
the high cost of tobacco products [37]. Increased taxes promote an increased proportion of 
smokers attempting to quit, and decrease the number of smoked cigarettes [38, 39]. Another 
effective tobacco control strategy is a smoke-free environment policy. This policy protects 
individuals from exposure of second-hand smoke [40] and prevents uptake of smoking 
among youth [41]. In the last two decades, a new tobacco control strategy has been 
established by applying anti-smoking and health warning message on cigarette packages to 
discourage the uptake of cigarettes and to encourage quitting; the effects of these warning 
messages on smokers are still under investigation [42]. These tobacco control strategies aim 
to help with reducing the prevalence of smoking and its associated health, social and 
economic costs, which have been in place for a number of decades [43]. In general, with 
these tobacco control strategies, daily tobacco smoking among the general Australian 
population has declined to historically low levels [43]. Data from 2013 show that, among 
people aged 14 or older, daily smoking declined from 15.1% in 2010 to 12.8%; similarly 
among adults (aged 18 or older) daily smoking declined from 15.9% in 2010 to 13.3% [43]. 
Tobacco control strategies have made a significant impact on cigarette consumption and 
smoking rates, predominately by preventing non-smokers from starting to smoke. But, as will 
be described below, sustained reduction among current smokers has proved difficult to 
maintain, predominantly because of dependence to nicotine.  
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2.2.2 Smoking cessation treatments 
Nicotine is an addictive substance binding to neuronal nicotine acetylcholine receptors 
(nAChRs) thus causing nicotine dependence, which is the primary determinant of persistent 
tobacco smoking [44]. Nicotine dependence is psychological and / or physical. Stopping 
nicotine intake – either partially or completely – can cause nicotine craving, anxiety, 
irritability, confusion, and difficulty sleeping, which are categorised as nicotine withdrawal 
symptoms [45]. Regular nicotine intake is required to maintain a nicotine level above a 
threshold point (the minimum amount of nicotine that produces reward effect). However, as 
there is no known safe level of smoking [8, 9, 46], complete quitting is clearly the most 
effective method of reducing smoking-related diseases. While most smokers report wanting 
to quit, sustained abstinence is elusive for most smokers. For example, in 2010, 
approximately 29% of Australian smokers reported they had tried to quit smoking but were 
unsuccessful, and 40% of smokers reported they had reduced their smoking [37].  
 
Quitting smoking is a huge challenge for smokers because of the addictive property of 
nicotine. In order to sustain a quit action and achieve cessation, another approach is to replace 
– or substitute – the nicotine via another source, for example using pharmacotherapy nicotine 
products, such as nicotine replacement therapy (NRT), or aid with non-nicotine medical 
therapy, such as varenicline and bupropion. Non-pharmacological smoking cessation services 
are also an effective way to support smoking cessation. 
 
2.2.2.1 Nicotine Replacement Therapy (NRT) 
Nicotine replacement products are effective interventions for smoking cessation [47]. NRT is 
developed as a method of replacing the nicotine that a smoker would otherwise obtain from 
smoking. It is believed that replacing the nicotine forgone during abstinence would reduce 
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withdrawal symptom severity and thereby make abstinence easier to sustain (see [48]). A 
variety of NRT products are available today, including nicotine patches, lozenge, gum, 
inhalator, and nasal spray.  
 
Nicotine gum is the earliest available type of NRT [49]. Nicotine is absorbed through 
the buccal mucosa, resulting in blood concentration approximately half that produced by 
smoking a cigarette [50]. However, there are limitations of using nicotine gum, such as oral 
and gastric side effects [51]. Other types of NRT subsequently were developed. Nicotine 
patch is a widely used form of NRT [52, 53]. The patch consistently and steadily delivers 
nicotine through the dermis into the blood stream. With nicotine patch treatment, the 
cessation rate can be increased by approximately two times compared with placebo treatment 
[54]. Other types of NRT, such as nicotine nasal spray, nicotine lozenge, have also been 
successfully developed for smoking cessation [49, 54].  
 
2.2.2.2 Varenicline and Bupropion – non-nicotine medical therapies 
Varenicline, a selective nicotine receptor partial agonist, is the newest medical smoking 
cessation product and more effective than using a single type of NRT [55]. It inhibits 
dopaminergic activation produced by smoking while simultaneously providing relief from the 
craving of smoking [56]. Varenicline treatment is started prior to the target quit day, and 
there is evidence that this promotes gradual reduction of smoking prior to quitting [57]. 
 
Bupropion is another commonly used non-nicotine therapy to aid smoking cessation, 
initially developed as an antidepressant [58]. It is a selective re-uptake inhibitor of dopamine 
and noradrenalin [59], and also acts as an antagonist of nicotine acetylcholine receptors [60], 
which reduces the craving to smoking and reduces symptoms from nicotine withdrawal [61]. 
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Reviewed literatures indicated that bupropion increased the likelihood of a successful quit 
attempt after at least six months [62]. The effectiveness of bupropion is comparable to NRT 
[62], but less effective than varenicline [63, 64]  
 
2.2.2.3 Non-pharmacological Smoking Cessation Treatments 
In additional to quit smoking medications discussed above, a variety of non-pharmacological 
smoking cessation services are also available for smokers wishing to quit, such as educational 
materials provided at clinics, hospitals, and telephone support quit lines [36, 65]. These 
services – broadly referred to as behavioural support – typical comprise education and advice 
designed to aid smokers as they attempt to quit. Behavioural support interventions can be 
delivered in a range formats, from static, written materials through to tailored content 
provided via mobile phone applications. Combining behavioural support and 
pharmacotherapy can improve the chance of maintaining long-term abstinence [66]. 
 
2.2.3 Smoking reduction  
As discussed above, smokers interested in quitting can chose from a variety of medications 
and services proven to improve their odds of achieving abstinence. Sadly, however, the 
absolute effectiveness of these tools is modest, with approximately 70% of aided cessation 
efforts ultimately ending in failure [55, 67]. One potential reason of the unsuccessfully 
quitting is the failure to use smoking cessation methods efficiently [52]; other factors also can 
influence the success of cessation. Nevertheless, it is clear that many smokers find it difficult 
to maintain complete abstinence, at least in the long term. For this reason, the tobacco control 
community has started to explore the benefits of smoking reduction.  
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Smoking reduction can be considered one form of harm reduction in those are not 
currently ready to quit [34, 68]. Smoking reduction is self-explanatory: it involves 
encouraging smokers who are either unwilling or unable to quit to reduce the CPD over a 
period of time, either as an end it itself, or as an initial step toward eventually quitting 
completely [33, 69]. Research study surveys have found that many smokers were interested 
in gradually reducing their smoking prior to making a quit attempt [34, 68], and a Cochrane 
review of the literature concluded that gradual reduction can be an effective method of 
achieving abstinence [33]. Given this evidence gradual reduction is increasingly seen as a 
viable approach for achieving abstinence [70]. 
 
As with cessation, a variety of interventions have been evaluated as reduction aids. A 
Cochrane review of the literature concluded that NRT effectively aided smokers to reduce 
smoking compared to placebo [71]. For instance, nicotine gum has been used in a smoking 
reduction study. This study indicated that there was two-fold sustained smoking reduction 
rate with nicotine gum use versus with placebo [72].  Other types of NRT, including nicotine 
inhalator (an oral device by delivering nicotine through buccal mucosa [47, 73]) and nicotine 
lozenge [7], have been reported to be effective in gradual smoking reduction. Nicotine 
patches have also been used 1-2 weeks prior to a target quit day (known as “preloading” [74]), 
which assist smokers to gradually reduce smoking.  
 
Interesting, data suggest that successfully reducing smoking aided with NRT is more 
likely to increase a quit attempt before the quit process [34, 47]. In other words, giving NRT 
prior to the quit attempt day may increase the likelihood of a successful quit attempt. 
Exploring the mechanism though which pre-treatment with nicotine patches influence 
smoking reduction is the focus of Chapter 6 of this thesis.  
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Finally, purely behaviour treatments have also been used to promote reduction [75]. 
However, the results of such treatments have been disappointing, with the majority of 
smokers unable to successfully maintain reduction in the longer-term.  
 
2.2.4 Limitations of existing NRT reduction treatments  
As noted above, numerous treatments exist that have been shown to aid reduction. There is 
substantial scope to improve the current offerings, however. Two key factors in the 
effectiveness of a nicotine replacement medication are the speed of nicotine delivery and the 
dose of nicotine obtained from NRT. Nicotine is absorbed into the bloodstream and delivered 
to the brain within 20 seconds after one inhalation of a cigarette [76], and the blood nicotine 
typically concentration ranges from 15-30 ng/L within 8 min [77, 78]. However, NRT 
products deliver nicotine substantially slower than smoking, with blood nicotine levels 
reaching a peak within 20 min [54, 79]. Even the fastest delivery product – nicotine nasal 
spray – still takes 10-15 min to reach the peak [80]. In addition, the amount of nicotine is not 
effectively absorbed. For instance, the nicotine intake level was lower while chewing gum 
compared to ad libitum, and this could be because nicotine was swallowed and underwent the 
first-pass metabolism [81]; and more frequent admission of nicotine gum is required [82]. In 
addition, even if the treatment could mimic the nicotine delivery that we see with smoking, it 
still would not replace cigarettes perfectly. 
 
2.2.5 New nicotine delivery products  
A new form of electronic nicotine delivery systems (ENDS), also known as vaporised 
nicotine products (VNPs), or colloquially referred to as electronic-cigarettes (“e-cigarettes”), 
was first introduced into cigarettes markets in 2004 [83]. VNPs are battery-operated devices 
capable of vaporising a nicotine solution instead of combusting tobacco and delivering 
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nicotine in an aerosolised form. The awareness and use of VNPs have grown rapidly over the 
past few years [84, 85]. Currently in the UK, there are over two million smokers using VNPs 
[86]. VNPs have become the most popular smoking products among youth in the US [87]. 
With the rapid increase in popularity, the design of VNPs has also rapidly updated. In the 
beginning, VNPs aimed to make people feel like they were having a normal cigarette [83]. 
Therefore, the VNPs were designed to resemble cigarettes and vaporise a liquid to generate a 
warm vapour or mist with each puff. The second generation of VNPs featured a larger 
capacity of batteries and the appearance looked like pens. Shortly after, VNP models were 
updated to third generation (also called ‘mods’, from modifications) [88]. The design and 
function have been modified to be more practical to meet the needs of VNP users. To date, 
the fourth generation of VNPs have emerged in the market. They feature automatic 
temperature control and adjustable dual airflow slots, which are more advanced and can 
deliver more nicotine (than the older three generation models). 
 
There are many reasons behind the rapidly increasing prevalence of VNPs. One 
reason is that they are considered safer than tobacco cigarettes. The daily exposure to 
nitrosamines (carcinogens formed from tobacco cigarettes, also known as tobacco-specific 
nitrosamines), based on an average consumption of 15 cigarettes per day, is estimated to be 
higher compared to that found after use of VNPs [89]. Two tobacco-specific nitrosamines, 4-
(methylnitrsamino)-1-(3-pyridyl)-1 butanone (NNK) and N’-nitrosonornicotine (NNN), are 
considered as major carcinogens that cause lung cancer. Other toxic chemicals such as heavy 
metals, carcinogenic polycyclic aromatic hydrocarbons and phenols have not been detected, 
with the exception of trivial amounts of mercury (0.17 ng per VNP) and traces of 
formaldehyde and acetaldehyde [90]. Research also evaluated emissions based on a toxicant 
emissions score and reported a score of 0 in VNPs compared with a score of 100–134 for 
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tobacco cigarettes. A UK panel of health experts concluded that, based on the available 
evidence, VNPs are at least 95% less harmful than cigarettes [91, 92]. However, the field is 
split in terms of their views on the safety of VNPs – and even their safety relative to 
traditional combustible cigarettes – with many study concluding that these products are not a 
safer alternative to smoking [93]. Work in this area is ongoing and will likely be contentious 
for years to come.  
 
Apart from the potentially lower risk associated with VNPs, another reason for their 
appearance is that VNPs have been reported to help people reduce or quit smoking. People 
have reported that VNPs can help to relieve the desire to smoke and reduce cigarette 
consumption [94-97]. Research has indicated that the majority of VNP users use VNPs for 
either complete (79%) or partial replacement (17%) of tobacco cigarettes [98] (although 
numerous other studies have reported negative findings). A laboratory-based study was 
conducted to monitor cigarette consumption after using VNPs [99, 100]. The consumption 
results demonstrated VNPs delivered nicotine into the blood stream but the plasma nicotine 
level was not as high as regular cigarettes. This study also observed nicotine abstinence 
symptom suppression and found that VNPs reduced cigarette craving and increased 
satisfaction with nicotine abstinence. The most recent research compared the appeal of VNPs 
to conventional cigarettes and smoking cessation aids. It was found that VNPs had similar 
appeals to cigarettes, fewer side effects, and suited personal preference [101]. Furthermore, 
VNPs deliver nicotine faster than traditional NRT [102, 103], potentially increasing their 
appearance among users looking for a replacement product that more closely mirrors the 
experience of smoking. Other studies also hypothesised that besides delivering nicotine to the 
lungs, VNPs might provide a coping mechanism for conditioned smoking cues by replacing 
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some of the rituals associated with smoking gestures (for example, the hand-to-mouth action 
of smoking) as well. Thus, VNPs might assist in coping with cigarettes cravings [97, 100].  
 
However, there is insufficient knowledge about how VNPs are used by smokers under 
real-world conditions, or whether these products actually help smokers to quit [104]. The 
evidence of VNPs relative profile to cigarette use, existing smoking cessation treatments, and 
the health risks, are still being explored. Such information is crucial to understanding how 
smokers use these devices and whether they may function as long-term cigarette substitutes. 
This knowledge could assist with regulation of the VNPs as well as examining the effects on 
individuals and at a public health level.  
 
Furthermore, unlike NRT products, VNPs are largely unregulated and as a result 
manufacturing quality is inconsistent [105]. Wide variations exist among brands and even 
models within a brand. There is also variability across solutions intended for VNPs. Solutions 
with nicotine concentrations ranging from 0 to 36 mg/mL can be found for purchase over the 
internet, and with flavours that come in categories with labels such as tobacco (e.g, “classic,” 
“sahara,” “Cuban cigar”), menthol (e.g, “menthol ice,” “peppermint patty”), dessert (e.g, 
“cotton candy,” “bubble gum,” “cheesecake”), and fruit (e.g, “apple,” “raspberry,” 
“watermelon”) [88]. The actual nicotine concentrations may differ from the product labelling. 
Even in the labelled nicotine free (0 mg) liquids, trace amounts of nicotine have been 
detected [105]. Moreover, there is no standard label definition of nicotine levels in cartridge 
solutions. Some solutions are labelled with ambiguous descriptions of nicotine levels, such as 
“low,” “medium,” or “‘high”. Research evaluated the accuracy of nicotine labelling and the 
presence of nicotine impurities and degradation products (known as nicotine by product 
during the producing process) in 20 VNP liquid samples [106].  They found that nicotine 
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levels were 85-121% of what was labelled, while nicotine degradation products were present 
at levels of 0-4.4% [106]. With the latest models, VNP users can mix their own solutions to 
customise flavours and / or nicotine concentrations. Mixing solutions in a non-hygienic 
environment carries the risk of contamination, and failure to use proper safety clothing and 
procedures could lead to accidental nicotine poisoning [101]. The varied and uncertain 
content of nicotine in solution makes interpretation of the use of VNPs in clinical studies 
difficult. In other words, it will be difficult to evaluate the strength of nicotine that generates 
the effect of reduction when using VNPs as intervention tools in smoking studies.  
 
2.3 Determination of smoking reduction 
2.3.1 Biological markers determination 
Smoking reduction is usually determined as a 50% reduction in cigarettes consumption [107, 
108]. However, the exact harm associated with each cigarette is not consistent. Smokers can 
compensate for reduction by smoking each remaining cigarette more intensely. Thus, simply 
measuring the reduction of cigarette consumption is not a sufficient determinant of harm 
reduction. To better quantify smoking reduction, biological markers are used to determine the 
harm exposure. Biological markers can be used to measure nicotine and its metabolites in 
biological fluids, thereby assessing exposure to tobacco products. 
 
After nicotine enters the body, it is extensively metabolised by a variety of liver 
enzymes and several metabolites have been reported in the literature [109] (Figure 2.1). 
Nicotine and its metabolites can be measured in blood, urine and saliva. Nicotine is 
metabolised by cytochrome P450 2A6 to cotinine, which is the main substance of nicotine 
metabolism. Cytochrome P450 enzyme is the main nicotine metabolising enzyme in humans 
[110]. About 66% of nicotine is metabolised to cotinine. Cotinine (around 75%) is further 
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metabolised to at least six secondary nicotine metabolites. The main metabolite is 3’-
hydroxycotinine, which accounts for around 33-40% of total nicotine in urine (Figure 2.2) 
[111]. Glucuronidation is another pathway of nicotine metabolism, which occurs for both 
nicotine and its metabolites – cotinine and trans-3’-hydroxycotinine. Glucuronidation is 
catalysed by uridine 5’-diphospho-glucuronosyltransferase enzyme producing nicotine-N-b-
glucuronide [112].  
 
Nicotine also forms other chemicals during curing process (Figure 2.3). 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-1butanone (NNK), N’-nitrosonornicotine (NNN), N’-
nitrosoanabasine (NAB), and N’-nitrosoanatabine (NAT) are formed by oxidation and 
nitrosation of nicotine. These nitrosamines are known as tobacco-specific nitrosamines, 
which are one group of carcinogens in tobacco products, and are also present in tobacco 
smoke [113]. NNK is extensively metabolised to 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol (NNAL), which is also a potent pulmonary carcinogen. NNAL has a chiral center at 
the carbinol carbon, thus is formed as both (R)- and (S)-NNAL enantiomers, however, this 
reaction is enantioselective. (S)-NNAL is the major form (>90%) produced using lung 
cytosolic fractions, lung microsomes formed primarily (R)-NNAL (>95%). (S)-NNAL is 
more readily formed from NNK, it is also more readily glucuronidated and detoxified by the 
phase II UDP-glucuronosyltransferase (UGT) than (R)-NNAL in monkeys and probably in 
humans [114]. NNAL is further metabolised to glucuronides. Two isomers of NNAL-
glucuronides, NNAL-O-glucuronide and NNAL-N-glucuronide, are detected in human urine. 
N-Glucuronidation, carried out by UGT 1A4 enzyme in human liver microsomes, has been 
implicated as an important mechanism of NNK detoxification pathway [115]. In addition, O-
glucuronidation also carried out by UGT enzymes but different UGT subtypes to N-
glucuronidation in liver micromes [116]. Although NNAL-N-glucuronides have been 
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reported to contribute substantially to total NNAL-glucuronides, both N- and O-
glucuronidation are important in the NNK detoxification pathway. Hence, urinary total 
NNAL (free NNAL and its glucuronides) is a biomarker of NNK intake from tobacco, and 
directly links NNK exposure to lung cancer development in humans [117].  
 
 
Figure 2.1 Nicotine metabolism pathway by liver [109]  
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Figure 2.2 Estimates percentage of average extraction of nicotine metabolites in urine [118] 
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Figure 2.3 Structure of tobacco specific nitrosamines forms from nicotine during curing 
process [113, 119] 
 
NNK is known as a tobacco-specific nitrosamine and is considered to be the most 
carcinogenic of the tobacco-specific nitrosamines. NNK is formed from nicotine and related 
compounds by a nitrosation reaction that occurs during the curing of tobacco. NNK is only 
present in tobacco products and tobacco smoke. It is assumed the uptake of NNK would be 
decreased with smoking reduction and cessation. NNK is metabolised to NNAL by 
cytochrome in P450 enzymes. The major metabolite, NNAL, is not present in tobacco 
products or tobacco smoke. In addition, NNK itself is not generally detected in the urine of 
laboratory animals treated with the compound, or in smokers’ urine. Therefore, NNAL can be 
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used as a biomarker of NNK exposure from tobacco [120]. The long biological half-life of 
NNAL also can be used to determine the exposure of tobacco-related harm [121]. 
 
NNAL levels in urine are at trace levels (in range of £0.5 ng/mL) [122]. To determine 
NNAL levels, the most frequently utilised assay involves solid phase extraction (SPE) 
associated with liquid chromatography technique for analysis [117, 123]. In addition, a new 
trend of SPE technique, online SPE associate with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), has also been used to determine NNAL levels [124]. This 
technique is directly connected to the chromatographic analysis without the prior purification, 
which is less time consuming than using the normal SPE methods. Other related methods 
have been used for NNAL analysis, such as, high-performance liquid chromatography-
tandem mass spectrometry (HPLC-MS/MS) coupled with liquid-liquid extraction [125, 126]. 
In this case, the liquid-liquid extraction involved chemical derivatisation of NNAL, and the 
extraction took one day to complete, being a costly and time consuming process.  
 
Because of the limitations of previous assays, there is an interest in developing a 
simple approach for NNAL determination. Ultra-performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS) was chosen. Compared to normal HPLC, UPLC uses 
small particle-packed columns with a small diameter, operates with high pressures and 
obtains better resolution of peaks. UPLC has advantages in terms of analysis efficiency and 
time-saving [127]. UPLC has been used successfully to measure metabolites in biological 
fluid in smoking cessation studies previously [128, 129].  
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2.3.2 Nicotine content measurement in VNPs 
To better quantify reduction, researchers have developed methods for assessing the 
constituents of nicotine substitutes as a method of measuring intake and exposure. To better 
understand VNPs (e-cigarettes), existing assays were mostly designed to analyse the levels of 
the main ingredients – nicotine – and its related compounds in e-cigarette liquids. For 
example, recent studies measured the nicotine and nicotine-related compounds in e-cigarette 
refill liquids using HPLC [106, 130]. These assays were restricted in application to a liquid 
cartridge, but there is a different cartridge type which is based on a fibrous material pad in the 
cartridge. Few assays have been applied to an e-cigarettes cartridge [131, 132]. Gas 
chromatography with the Thermionic Specific Detector (GC-TSD) [131] and HPLC-UV [132] 
have been used in one study. A major limitation in this study [131] was that quinolone was 
used as internal standard which has different chemical properties from nicotine. As a result, 
assay performance may not accurately represent the response of nicotine in the e-cigarette 
cartridge. Gold standard analytical procedure should generally use deuterated internal 
standards with mass spectrum based detection methods.  
 
2.4 Research purpose  
Tobacco harm reduction is designed to encourage smokers to gradually increase the use of 
treatment (e.g., NRT) and cut down cigarette consumption. Reduction might have an impact 
on increasing quit attempts and achieving successful cessation. Biological markers and the 
constituents of nicotine substituted products are used to measure tobacco intake and exposure. 
A variety of methods have been used to measure both biological markers of tobacco exposure 
and the constituents of nicotine products. However, there are limitations with existing 
methods to measure actual tobacco exposure. The research purpose is to 1) develop improved 
measures of the constituents of medical nicotine products, particularly in VNPs; 2) develop 
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measures of biological markers and apply these to assess smoking reduction; and 3) 
effectively use pre-quit treatments and accurately study smoking behaviour and its 
consequences.  
 
Firstly, with the high interest in tobacco harm reduction, a variety of medical nicotine 
products have been utilised to assist harm reduction. However, if the nicotine content in the 
products is unknown or inconsistent, it is difficult to say that the products can be useful in 
assessing smoking reduction, particularly since the introduction of vaporised nicotine 
products (VNPs). With this question in mind, Chapter 3 of this thesis includes the 
development of an assay to determine the nicotine content in VNP products, and the 
application of this assay to VNP products to investigate whether the nicotine content is 
consistent with the label and consistent between product batches (Study 1). Knowing the 
nicotine content is of critical importance to allow a better interpretation of clinical outcomes 
while using these new products in future smoking reduction studies. 
 
Secondly, reduced CPD is normally defined as the main determinant of smoking 
reduction. However, smoking behaviour can vary between individuals.  Assessing the success 
of harm reduction by simply counting the CPD is not a sufficient measurement of harm 
reduction. Cigarette numbers used as the only physical determinant is not sufficient to 
monitor smoking reduction. Biological markers are normally used to assess smoking and 
nicotine intake. Current methods for NNAL determination involve complex sample 
preparation. An easier approach is required for testing NNAL levels in smokers’ urine. 
Chapter 4 of this thesis contains the development of an assay for determining NNAL levels in 
human urine (Study 2), and Chapter 5 applies this NNAL assay to smokers’ urine that has 
been collected from a smoking cessation study (Study 3). 
  Chapter 2	
	 26	
 
Thirdly, a gradual reduction in smoking by giving a pre-loading treatment prior to the 
target quit day can help to increase the quit attempt by reducing the satisfaction of smoking, 
and improve the effectiveness of treatment [52]. Pre-quit nicotine patches have been utilised 
to give the pre-loading treatment 1-2 weeks prior to the target quit day in a previous cessation 
study [133]. Over the course of the pre-quit period, there was a reduction in satisfaction with 
smoking and in the number of self-reported cigarettes smoked, and that the reduced 
satisfaction might drive the smoking reduction and promote interest in quitting. Varenicline, 
has also been suggested to have similar efficacy as pre-quit patch treatment to reduce the 
satisfaction from smoking. However, the mechanism of reduction of satisfaction and smoking 
rate has not explicitly been tested before [57]. In order to gain a better understanding of 
smoking reduction, in Chapter 6 of this thesis, a clinical trial has been conducted to utilise 
two pre-quit treatments, nicotine patch and varenicline, to explore the effect of the two pre-
quit treatments on reduction of daily smoking rate and satisfaction with smoking; and test the 
relationship between the satisfaction with smoking and smoking rate during the pre-quit 
period (Study 4). Monitoring such reductions may help to better tailor treatments.  
 
The final two chapters of this thesis are a general discussion and conclusion regarding 
assays for determining smoking harm reduction, the determination of the constituents of 
nicotine substitute products, and biological markers of actual smoking harm exposure. These 
measures should assist the study of smoking behaviour and its consequences. 
 
	
 
 
 
 
 
 
Chapter 3: Determination of Nicotine in 
Cartridge-based Electronic Cigarettes 
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3.1 Background 
Electronic cigarettes (e-cigarettes) as a new form of nicotine delivery device are evolving 
rapidly. However, due to lack of standards for manufacturing and regulations of e-cigarettes, 
there are concerns about the safety of their use. One of the main concerns is quality control 
during their manufacturing, especially the accuracy of labelling where nicotine content varies 
from manufacturer to manufacturer [10, 105, 131]. For instance, with many models, it is 
unknown whether nicotine content in the e-cigarette cartridge corresponds to the content 
claimed on the label. The properties of e-cigarettes are also important for producing vapour 
and delivering nicotine. Because there is lack of manufacturing standard for e-cigarette 
products, the design properties – for example battery power, airflow, pressure drop, etc. – 
vary among devices [134]. These factors influence the production of aerosol density from 
puff-to-puff, and subsequently influence the experience of using e-cigarettes and nicotine 
delivery. The variability of e-cigarette properties could result in the highly varied delivery of 
actual nicotine amounts in the vapour [105, 135, 136].  
  
Only a few laboratory analytical studies have investigated the actual nicotine content 
in e-cigarette cartridges [105, 131]. One study has reported a method using methanol as an 
extraction solvent. This method used a platform shaker for 90 min extraction, then the 
extraction solution was analysed by high performance liquid chromatography (HPLC) [105]. 
While the authors reported 99% recovery of nicotine from the cartridge, the recovery was 
calculated simply based on a standard solution of nicotine, rather than extraction of nicotine 
from the actual sample matrix (the e-cigarette fibrous pad in this case). This is a major 
limitation in terms of analytical quality assurance, and inferior to the analytical approach 
taken in our work. In addition, this method prepared the standard solution of nicotine in 50% 
methanol in water and serially diluted with 10% acetonitrile in water, which was different to 
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the extraction solution (methanol). Differences in solvents used for extraction and standards 
can have a significant effect on instrument response (sensitivity). Furthermore, recovery 
estimates will also potentially vary significantly based on the types of cartridge materials 
used in e-cigarettes. 
 
Therefore, there is an important need to develop and validate ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) technique for determination of 
nicotine content in e-cigarette matrices. The aim of the study was to develop an effective 
quantitative assay, and apply it to evaluate nicotine content in one specific type of e-cigarette 
product – fibrous pad based e-cigarette cartridges – using deuterated standards to obtain 
reliable recovery where blank cartridges are not available. It is of particular importance when 
interpreting the outcomes of studies designed to evaluate the safety of e-cigarettes, and / or 
their usefulness for smoking cessation, and / or smoking reduction, particularly given the rate 
at which new products are emerging. 
 
3.2 Study design 
The main ingredient in an e-cigarette is nicotine that is absorbed onto a fibrous material pad 
in the cartridge. An assay was designed for extracting nicotine from the fibrous pad and 
measuring the nicotine content. For investigating the extraction efficiency and assay 
validation, standard nicotine should be spiked onto a blank e-cigarette cartridge fibrous 
material pad. However, blank fibrous pads were not available for assay development because 
nicotine has been detected even in labelled nicotine free cartridges. Three approaches were 
used for the extraction. Firstly, an aliquot volume of nicotine-d4 solution, used as an external 
standard, was spiked into the cartridge fibrous pads (n= 3) using a syringe and then the 
syringe was flushed twice with methanol. These samples were defined as the nicotine-d4 
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group. Secondly, an aliquot of nicotine standard solution, that contained nicotine content 
equivalent to the content in the cartridge, was spiked into the cartridge pads (n= 3) by using 
the same syringe, then the syringe was flushed twice with methanol. In addition, nicotine-d4 
was spiked into the pads at the same amount as the nicotine-d4 group. These samples were 
defined as nicotine standard addition group. Thirdly, the same process but an aliquot volume 
of methanol without nicotine was spiked into the cartridge pads (n= 3), which was defined as 
the control group. All the samples were placed in an Erlenmeyer flask and added to 50 mL of 
extraction solvent. The flasks were placed in the ultra-sound bath for a different time duration 
of extraction at ambient temperature. After the sonication, nicotine-d4 solution was added as 
an internal standard in the extract of the control group. All the extraction solutions from three 
groups were further diluted with deionised water and analysed by UPLC-MS/MS. 
 
3.3  Materials 
3.3.1 Reagents 
Nicotine standard (1.01 g/mL, 1 mL), purchased from Sigma Aldrich Co. (Saint Louis, 
Missouri, USA) was used for the preparation of standard solutions. Deuterated nicotine 
(nicotine-d4) (100 µg/mL, in 1 mL Acetonitrile), was purchased from Cerilliant (Cerilliant 
Corporation, QLD, Australia), and used as an external standard. Methanol (50% v/v) in 
deionised water (methanol: MERCK KGaA, Darmstadt, Germany) and ethyl acetate (Sigma 
Aldrich CO., Saint Louis, Missouri, USA) were used as the extraction solvents. Trypan Blue 
solution (0.4%) (Sigma Aldrich Co., NSW, Australia) and Crystal Violet (0.1% w/v) (Oxid, 
West Heldleberg, VIC, Australia) were used to determine the penetration property of the 
fibrous pad. 
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3.3.2 E-cigarette cartridge samples 
E-cigarettes (labelled as containing nicotine16 mg; Elusion New Zealand Holdings Ltd, New 
Zealand) were used. Ingredients were adsorbed onto a fibrous material pad in the e-cigarette 
cartridges. The ingredients were shown on the package, and included; nicotine, propylene 
glycol, glycerine, and tobacco flavour agent. Nicotine was classified under Schedule 7 
substances of the Poisons Act 1971, regulation 74 of the Poisons Regulation 2008. We 
received authorisation from Vice-Chancellor of the University of Tasmania to purchase, store 
and use these products only for laboratory-based research. 
 
3.3.3 Instrumentation 
A Water Acquity® H-class UPLC system (Milford Massachusetts, USA) coupled to a Waters 
Xero® MS/MS using MassLynx™ software was used to detect and quantify the extracted 
nicotine solution. Chromatography was performed on a Water Acquity® UPLC BEH C18 
column (2.1 ´ 100 mm ´ 1.7 micron particles). The laboratory equipment that were used 
during the experiments included an ultrasound bath (Bandelin Sonorex RK 100, Germany); 
vortex mixer type 37600 (Thermolyne Corporation, Dubuque, Iowa, USA); micropipette 
(Biohit, Germany). 
 
3.3.4  UPLC solvent and analytical conditions 
The UPLC solvent system consisted of mobile phase A (0.4% ammonia) and B (acetonitrile). 
The flow rate was 0.4 mL/min, with 100% A for 0.3 min, then a linear gradient to 30% A and 
70% B at 4 min, before immediate re-equilibration to the initial condition for 3 min. The MS 
was operated in positive electrospray ionisation mode with multiple reaction monitoring 
(MRM). The ion source temperature was 150 °C, the desolvation gas was nitrogen at 1000 
L/h, the desolvation temperature was 300 °C and the capillary voltage was 2.8 KV. The 
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MRM transitions monitored for quantitation were m/z 163.1→130.1 (nicotine), m/z 167.1→
134.1 (nicotine-d4). 
 
3.3.5 Standard stock solution preparation  
Nicotine standard (1.01 g/mL, 4.29 mg), liquid form at ambient temperature, was weighed 
and made up to 10 mL in volumetric flask with deionised water. A large volume of nicotine 
stock solution was also prepared by weighting 102.36 mg of nicotine and made up to 50 mL 
in volumetric flask with deionised water.  
 
3.3.6 Calibration curve solution 
The correlation coefficient (r2) was used to estimate the linearity over a concentration range 
from 50 to 400 ng/mL for the calibration solutions of nicotine in methanol (50% v/v) in 
deionised water. The calibration solutions were prepared from the nicotine stock solution 
(4.29 mg/10 mL). Because the content of nicotine in the e-cigarettes was unknown, validation 
of the method was performed at two different levels of nicotine; low (200 ng/mL) and high 
(400 ng/mL). These values were equivalent to 10 mg and 20 mg of nicotine content in e-
cigarette cartridges respectively, and were anticipated to cover the expected e-cigarette 
content range. 
 
The dilution methods might be a factor that influences the linearity of calibration 
curve. We designed serial dilution and separated dilution of the standard solutions. With 
serial dilution, the nicotine standard solution was diluted from 400 ng/mL to 50 ng/mL. With 
separated dilution, the nicotine standard solution was diluted from 400 ng/mL to 200 ng/mL; 
100 ng/mL; and 50 ng/mL separately. Ten microliters of nicotine-d4 were added into each 
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concentration of nicotine solution. The mixed solution was analysed by UPLC-MS/MS to set 
up the standard calibration curve.  
 
3.4  Extraction development 
3.4.1 Extraction solvent effects 
In order to investigate the appropriate solvent for extraction, we compared the 
chromatography response of nicotine standard in four solvents: methanol and ethyl acetate 
which were used as reference extraction solvents [105, 131], and another two solvents, 
50% v/v methanol in deionised water and 100% deionised water. Nicotine (1 µg) was added 
in 50 mL of each solvent. The flasks were placed in the ultra-sound bath for 15 min at 
ambient temperature (20 to 25 °C). After sonication, the extract was further diluted with 
deionised water (1000-fold) before determining the nicotine content using UPLC-MS/MS.  
 
3.4.2 Penetration property of cartridge fibrous pad 
Nicotine-d4 was investigated as an external standard by spiking it onto the surface of a 
cartridge fibrous pad and allowing it to penetrate into the matrix. The nicotine-d4 was used to 
determine the extraction efficiency and measure the nicotine amount in the pad. However, it 
was unclear whether the nicotine was absorbed into or adsorbed onto the cartridge fibrous 
pad. The penetration property of the fibrous pad was therefore investigated. Two water 
soluble dye were used, Trypan Blue solution (0.4%) and Crystal Violet (0.1% w/v). Ten 
microliters of each dye were spiked onto the sliced e-cigarette cartridge fibrous pad, allowing 
the solution to penetrate into the pad and photographed after 5, 10, and 15 min of penetration. 
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3.4.3 Nicotine-d4 external standardisation 
As mentioned before, nicotine-d4 was used as an external standard by spiking onto the 
surface of the e-cigarette cartridge fibrous pad. In order to obtain a reliable recovery estimate, 
another requirement was that the external standard must be fully spiked into the sample 
cartridge penetrating the matrix. Two nicotine-d4 spiking methods were investigated; an 
HPLC syringe technique versus a micropipette technique. Ten microliters of nicotine-d4 (1 µg) 
were spiked onto the surface of the fibrous material using a 25 µl glass HPLC syringe with a 
stainless steel blunt tip or micropipette with disposable plastic tip. The solution was allowed 
to soak into the fibrous pad for 10 min. The pads then underwent the extraction process.  
 
3.4.4 Extraction solvent 
Ten microliters of nicotine-d4 (1 µg) were spiked onto the surface of the e-cigarette cartridge 
fibrous pad (nicotine-d4 group, n= 4); ten microliters of nicotine-d4 (1 µg) and ten microliters 
of nicotine standard (16 mg) were spiked onto the surface of the fibrous pad (nicotine 
standard addition group, n= 4); and ten microliters of methanol were spiked on the fibrous 
pad (control group, n= 4); and allowed to penetrate into the fibrous pad for 10 min. The pads 
were then placed in Erlenmeyer flasks and 50 mL of methanol, ethyl acetate, 50% v/v 
methanol in deionised water, and 100% deionised water were added to different flasks to 
investigate the effect of extraction solvent. The flasks were placed in the ultra-sound bath for 
15 min at ambient temperature. After sonication, the same amount of nicotine-d4 was added 
into control group samples, and all the extracts were further diluted with deionised water. 
Given that nicotine-d4 (external standard) and nicotine analyte were different in concentration, 
two separate dilutions of the extraction solutions were used; 50-fold dilution for nicotine-d4 
and 1000-fold for nicotine determinations respectively. Both diluted extraction solutions were 
then analysed using UPLC-MS/MS.  
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3.4.5 Extraction time  
Extraction time was investigated as a determinant of extractive capacity. Cartridge fibrous 
pads (n= 3) were removed from the e-cigarette cartridge chamber and extracted as outlined 
above for different time periods. Samples were extracted using ultra-sound bath (15 min), 
ultra-sound bath (30 min), shaker (60 min) and shaker (120 min) at ambient temperature. The 
extract was further diluted with deionised water before analysed by UPLC-MS/MS. 
 
3.4.6  Application of assay on e-cigarettes batches 
E-cigarette cartridge fibrous material was removed from the cartridge chamber using a pair of 
tweezers. Ten microliters of nicotine-d4 (1 µg) were spiked onto the fibrous material using a 
micropipette and allowed to penetrate into the material for 10 min. The fibrous material was 
then placed in an Erlenmeyer flask with 50 mL of the appropriate extraction solvent (50% v/v 
methanol in deionised water). The flask was placed in the ultra-sound bath for 15 min at 
ambient temperature. After sonication, the extract was further diluted with deionised water. 
Given that nicotine-d4 and nicotine analyte were orders of magnitude different in 
concentration, two separate dilutions of the extraction solutions were used; 50-fold dilution 
for nicotine-d4 and 1000-fold for nicotine determinations respectively. Both diluted extraction 
solutions were then analysed using UPLC-MS/MS. 
 
3.4.7 Assay performance 
Acceptance criteria for the assay were defined as intra-day accuracy and precision less than 5% 
at these levels. Within-batch intra-day precision was evaluated by repeated injections (n= 5) 
of nicotine standard solution (400 ng/mL) throughout the course of one day. Intra-day 
accuracy was calculated from the calibration curve at the 200 ng/mL and 400 ng/mL solution. 
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Because blank e-cigarette cartridges were not available, the recovery of nicotine was 
calculated based on the nicotine-d4 content extracted from the fibrous material compared to a 
nicotine-d4 standard diluted to a concentration equivalent to 100% theoretical recovery from 
the e-cigarettes. Recovery was calculated both intra-day (n= 5) and inter-day (n= 6). Limit of 
detection (LoD) and lower limit of quantification (LLoQ) were determined from the signal-
to-noise ratio of replicate injections (n= 5) at the 50 ng/mL level for nicotine, with LoD 
defined as a signal-to-noise ratio of 3 and LLoQ as a signal-to-noise ratio of 10 [137]. Carry 
over was assessed by injecting blank deionised water following injection of standards 
containing 400 ng/mL nicotine; selectivity was assessed as analyte response in blank 
deionised water (n= 5).  
 
3.5 Results and discussion 
3.5.1 Method development 
This method was designed to extract and measure the content of nicotine present in e-
cigarette cartridges consisting of a fibrous pad. The assay is particularly useful where blank 
cartridges are not available. Results in our laboratory and others have shown that even 
nicotine free labelled cartridges may contain nicotine [105]. Previous studies have shown that 
nicotine content did not match the label claim with some brands [105, 131]. But these assays 
have had minimal validation with respect to recovery of analytes from the cartridge pad. This 
current assay used a known content of nicotine-d4 as a standard spiked onto the fibrous 
cartridge pad material, which was then compared with the nicotine-d4 standard using external 
standardisation to calculate the recovery of nicotine-d4 from the pad. During the development 
of the assay, different extraction solvents were investigated. The chromatogram peak area of 
nicotine in three approach groups was investigated in four extraction solvents. Compared to 
deionised water (100%), the mean peak area of two replicates of nicotine in methanol 
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solution was 136 ± 0.01%, 50% v/v methanol in deionised water was 76 ± 2.7%, and ethyl 
acetate solution was 69 ± 5.1%. The results have shown that the choice of solvent influences 
nicotine recovery and response with up to 50% of variation between solvents.  
 
It was found that care was required with regard to the exact amount (~1 µg) of 
nicotine-d4 spiked onto the fibrous pad material. The penetration of the external standard 
solution from the surface was confirmed visually. The two water soluble dyes that could be 
seen absorbed into the pad material with no observable difference between 5, 10 and 15 min 
(Figure 3.1). A glass HPLC syringe was used to spike nicotine-d4 onto the pad, and a 
micropipette was used to spike nicotine-d4 as well. These two methods resulted in different 
recoveries of nicotine-d4; ~50-60% by using the HPLC syringe technique and 81% by using 
the micropipette technique. The recovery of nicotine-d4 was lower with the syringe than with 
the micropipette, possibly due to capillary action (Figure 3.2). 	  
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Figure 3.1 Ten microliters of two water-soluble dyes, Trypan Blue solution (0.4%) (left side 
fibrous pad) and crystal violet (0.1% w/v) (right side fibrous pad), were spiked onto the sliced 
e-cigarette cartridge fibrous pad, allowing the solution to penetrate the pad. A= 0 min after 
spiking; B= 5 min after penetration; C= 10 min after penetration; D= 15 min after penetration 
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Figure 3.2 The dye solution remained in the syringe when the HPLC syringe was used to spike 
nicotine-d4 into the cartridge fibrous pad  
 
In addition, extraction time would be expected to be a determinant of extractive 
capacity. Therefore, three extraction time periods were investigated, 15 min, 30 min, and 
60 min. The recovery of nicotine-d4 was 86% with 15 min ultra-sound bath, 79% with 30 min 
ultra-sound bath and 83% and 84% with 60 and 120 min on a shaker. The recovery results 
showed that there was a little difference between these so the shortest time was chosen for 
this assay.  
 
A significant barrier in the development of this assay was the large difference 
between amounts of nicotine-d4 standard that could be used economically and the nicotine 
concentrations in the e-cigarette fibrous core (approximately 16,000-fold). It was not feasible 
to dilute the extraction solvent to a level whereby both analytes were in the calibration range 
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of the instrument. Nicotine-d4 is relatively expensive and it is not economical to spike at 
concentrations equivalent to nicotine. Therefore, the extraction solution was diluted 
separately, which necessitated two different analyses for each sample; 1000-fold dilution for 
nicotine and 50-fold dilution for nicotine-d4, and similarly for the external standard 
calibration solutions. Using the nicotine-d4 spiked onto the cartridge pad, and under our 
extraction conditions, we consistently demonstrated greater than 80% recovery. 
 
3.5.2 Assay performance 
The chromatograms for nicotine and nicotine-d4 in solvent extracted from an e-cigarette 
cartridge are shown in Figure 3.3. Nicotine and nicotine-d4 eluted at 3.85 and 3.82 min 
respectively. Nicotine standard is a viscous liquid, which might cause a deviation between the 
theoretical amount and the actual measured amount when utilising micro-pipette to measure 
and transfer volumes. For instance, if preparing nicotine standard solution with a theoretical 
nicotine amount of 400 µg, due to the viscosity of nicotine, the actual measured amount 
might less than 400 µg. Hence, nicotine standard was weighed using Mettler Toledo balance 
(0.001 g) to prepare the nicotine standard stock solution. The nicotine standard calibration 
curve was linear over the range of 10 ng/mL to 400 ng/mL with an r2= 0.9998 (Figure 3.4). 
Intra-day accuracy was 0.7% and 0.5% at 200 ng/mL and 400 ng/mL levels respectively. 
Intra-precision [relative standard deviation (RSD%)] was 3.1% and was consistent when 
repeated on a second day (3.6%). The LoD was 0.04 ng/mL and LLoQ was 0.14 ng/mL. The 
recovery of nicotine-d4 extracted from the cartridge pad using 50% v/v methanol in water was 
81.5% ± 3.7 and 82.4% ± 1.3 for intra-day and inter-day respectively (mean ± SD). In the 
nicotine standard addition group, there was a corresponding increase in nicotine peak area 
compared with nicotine-d4 group and control group.  	 	
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Figure 3.3 Sample chromatograms showing nicotine-d4 external standard (top) and nicotine 
(bottom) recovered from e-cigarettes cartridge fibrous pad  
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Figure 3.4 The nicotine standard calibration curve was linear over the range of 10 ng/mL to 
400 ng/mL with an r2= 0.9998. Error bar represents the standard deviation 
 
3.5.3 Nicotine content in e-cigarette batches 
The developed and validated assay was applied to e-cigarette batches (same brand of e-
cigarette as noted in 2.2.2). The recovery of nicotine-d4 extracted from the cartridge pad was 
81.5% ± 3.7 (mean ± SD). Taking into account recovery, nicotine content in the e-cigarette 
cartridge samples, 11.9 ± 1.3 mg (mean ± SD), and the variation of nicotine content between 
cartridges within batch as well as between batches was not significant (Figure 3.5). With this 
method, significant differences were found between labelled and actual content of nicotine in 
e-cigarette cartridges. The nicotine content of all the cartridge samples was ~25% lower than 
the labelled content (16 mg). This result indicated that the nicotine content information on the 
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product package provided by the manufacturer may mislead customers and that direct 
comparison with e-cigarettes is difficult, although it is well-known that smokers will titrate 
the dose obtained from smoking [99]. How e-cigarettes are used can impact on the actual 
amount of nicotine absorbed [138].  
 
 
 
Figure 3.5 Nicotine content in one brand of e-cigarette cartridges (all depicted as mean ± 
95% confidence intervals). A nicotine standard (16 mg) was shown on the left (n= 8 replicates) 
and compared with four packs of the same brand of e-cigarette and from each pack a random 
sample of five e-cigarette cartridges were analysed (n= 3 replicates) 
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3.6 Conclusion 
An efficient assay was developed to measure the nicotine content in e-cigarette cartridges 
containing fibrous pads in propylene glycol and glycerine solvents where blank e-cigarettes 
are not available. The content of nicotine in the e-cigarette cartridges can be effectively 
determined by UPLC-MS/MS. Application of this assay demonstrates that, at least with the e-
cigarettes we tested, the amount of nicotine stated on the label varied substantially from that 
observed analytically. The accurate determination of the quantity of nicotine in e-cigarettes 
has important implications for both consumer safety and the further study of these devices.  
 
	
 
 
 
 
 
 
Chapter 4: Determination of 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) in Urine 
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4.1 Background 
Thousands of chemicals are generated during curing tobacco, and most of them are toxic and 
carcinogenic [139]. Tobacco-specific nitrosamines (TSNAs) are one group of carcinogens in 
tobacco products and are also presented in tobacco smoke [113]. Among the tobacco-specific 
nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is one of the most 
prevalent of these compounds presented in both unburned tobacco and cigarette smoke. It is a 
remarkably effective lung carcinogen in laboratory animals, inducing lung tumours in rats, 
mice, and hamsters independent of the route of administration [113, 140]. NNK, which is 
generated from nicotine by oxidation and nitrosation during the curing process, has been 
classified as a human carcinogen (Group I) by the International Agency for Research on 
Cancer [139]. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), the major metabolite 
of NNK, is also a potent pulmonary carcinogen [120]. NNAL is further metabolised to N- 
and O-glucuronide conjugates, which are excreted in urine together with free NNAL [115, 
140]. Total NNAL (free + glucuronide) is not presented in cigarette smoke, hence it is 
considered an effective biomarker of NNK uptake [120]. The long biologic half-life of 
NNAL, which is 10-18 days, can also be used to determine the exposure of tobacco-relate 
harm [121].  
 
NNK is formed from nicotine and related compounds by a nitrosation reaction that 
occurs during the curing of tobacco. Hence, the uptake of NNK would be decreased with 
smoking cessation. NNAL levels in urine are typically in range of less than 0.5 ng/mL, and 
vary from individual to individual [122]. Measuring low levels of NNAL in a urine matrix is 
a significant analytical challenge. Urine matrix might interfere the extraction of low level 
content, typically like NNAL levels at 0.5 ng/mL. In previously reported liquid 
chromatographic assays, NNAL measurement utilised a solid phase extraction (SPE) 
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technique to concentrate naturally occurring NNAL levels prior its analysis [124, 141]. 
However, the reported SPE methods have been complex, with multiple steps, including two 
SPE extractions with different stationary phase and solvents. An easy to approach assay is 
needed to determine the NNAL level in smokers’ urine. 
 
Recent new extraction techniques, including dispersive liquid-liquid micro-extraction 
(DLLME), dispersive liquid-liquid micro-extraction based on the solidification of floating 
organic droplets (DLLME-SFO), are simple, quick, inexpensive, and efficient techniques 
with a high enrichment factor for sample preparation (Table 4.1). These techniques are 
particularly applicable for trace level analytes in a sample, such as in urine matrices. DLLME 
and DLLME-SFO assays are generally established on a ternary component solvent system, in 
which an appropriate disperser solvent is introduced to help the dispersion of an organic 
extraction solvent into an aqueous sample and improve the extraction efficacy [142-144]. The 
use of DLLME or DLLME-SFO to analyse NNAL in urine samples has not been reported so 
far. Apart from these relatively new techniques, liquid-liquid extraction is a traditional and 
frequently used technique in separation and analytical chemistry. UPLC-MS/MS is a 
sensitive and selective assay that we developed previously for the determination and 
quantification of the two major nicotine metabolites, cotinine and trans 3’-hydroxycotinine, 
in smokers’ urine [128]. UPLC-MS/MS assay has not been applied to measuring NNAL 
levels in previous research studies. Therefore, the objective of this study was to develop a 
simple rapid assay by using UPLC-MS/MS combined with an efficient but easier sample 
preparation methodology to determine NNAL levels in urine samples. Additionally, this 
assay applied to smokers’ urine samples to investigate both free and total NNAL levels as 
well as to assess tobacco exposure.  	 	
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4.2 Study design 
Five extraction assays, including DLLME, DLLME-SFO, derivatisation of NNAL, SPE and 
liquid-liquid extraction, were designed for NNAL extraction. After the extraction, the NNAL 
extract was evaporated with nitrogen gas and reconstituted in deionised water for UPLC-
MS/MS analysis. Assay validation was processed using the spiked NNAL standard and 
deuterated NNAL (NNAL-d3) blank urine samples. The extraction efficacy would be directly 
affected by the selection of extraction and disperser solvents during each extraction in the 
assay development. The extraction efficacy could also be determined by ultra-sound bath 
sonication, as well as different extraction durations. The recovery of NNAL was used to 
determine whether the assay was suitable for NNAL extraction. 
 
4.3 Materials 
4.3.1 Reagents 
NNAL standard (10 mg) and deuterated NNAL (NNAL-d3) (1 mg), were purchased from 
Toronto Research Chemicals Inc. (North York, ON, Canada), and used for the preparation of 
standard solutions and internal standard respectively. HPLC-grade methanol (Merck KGaA, 
Darmstadt, Germany) was used to prepare the standard solutions. Ethanol (Merck Pty Ltd, 
VIC, Australia), acetone (Wesfarmers CSBP Ltd, WA, Australia) and acetonitrile (Sigma-
Aldrich, NSW, Australia) were used as the disperser solvents. Dichloromethane (DCM) 
(Waters Associated, Milford, MA, USA), 1-undecanol (Sigma-Aldrich, MO, USA), hexane 
(Fisher Chemical, Pittsburgh, USA), toluene (Merck KGaA, Darmstadt, Germany), and 
HPLC-grade ethyl acetate (Merck KGaA, Darmstadt, Germany) were used as extraction 
solvents. Trifluoroacetic acid (TFA) (0.1% in water (v/v), pH 3, Ajax Chemical, NSW, 
Austraia) and ammonia solution (28%, pH 10, Ajax Chemical, NSW, Australia) were 
prepared to adjust urinary pH. 
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4.3.2 Instrumentation and apparatus 
The UPLC-MS/MS instrument and the laboratory equipment have been described in 3.3.3. 
Reacti-Vap Evaporator with Reacti-therm I heating module (ThermoFisher scientific, 
Victoria, Australia) was used to control the evaporation temperature and evaporate the 
extracted organic phase. 
 
4.3.3 UPLC solvent and analytical conditions 
The UPLC solvent system and column condition were the same as described in 3.3.4. 
Injection volume was 20 µL. The MS was operated in positive electrospray ionisation mode 
with MRM. The ion source temperature was 130 °C, desolvation gas was nitrogen at 950 L/h, 
desolvation temperature was 450 °C, and the capillary voltage was 2.8 kV. Cone voltage was 
optimised for each MRM transition at 24 V. Dwell time for each transition was 78 msec. 
 
4.4 Methodology 
4.4.1 Preparation of calibration solution 
A standard stock solution of NNAL (200 µg/mL) was prepared by dissolving 10 mg of 
NNAL standard in 50 mL of methanol in a volumetric flask. Similarly, deuterated NNAL 
(NNAL-d3) stock solution (100 µg/mL) was prepared by dissolving 1 mg of NNAL-d3 in 
10 mL of methanol in a volumetric flask. The stock solutions were stored in a refrigerator at 
4 °C for up to six months. NNAL working standard solution (5 ng/mL) and NNAL-d3 
internal standard solution (5 ng/mL) were freshly prepared from the stock solutions and used 
within two days. Calibration standard solutions were prepared by spiking NNAL working 
standard solution in blank urine over an ascending concentration range of 1 to 400 pg/mL, 
and spiked with 100 pg/mL of internal standard. 
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4.4.2 UPLC-MS/MS performance 
The MS was operated in positive electrospray ionisation mode with MRM. NNAL working 
standard solution (5 ng/mL) and NNAL-d3 internal standard solution (5 ng/mL) spiked in a 
blank urine was prepared for the full scan of NNAL and NNAL-d3 mass range. The retention 
time of NNAL and NNALd3 was monitored by using UPLC. 
 
4.4.3 Assay performance validation  
Correlation coefficient (r2) was used to estimate the linearity of NNAL in the range from 1 to 
400 pg/mL. Acceptance criteria for the assay were defined as the intra-day accuracy and 
precision values below an RSD% of 15% at the 5, 20 and 100 pg/mL of standard samples, 
which represented low, medium and high levels of NNAL in smoker’s urine. The recovery of 
NNAL was calculated based on the NNAL-d3 concentration in urine samples compared to a 
NNAL-d3 standard prepared to a concentration equivalent to 100% theoretical recovery from 
the blank urine samples. The LoD and LLoQ were determined from the signal-to-noise ratio 
of replicate injections (n= 6) at 5 pg/mL of a standard sample with LoD defined as S/N= 3 
and LLoQ as S/N= 10 [149]. Carry over was assessed by injecting a blank deionised water 
sample following injection of a standard containing100 pg/mL of NNAL. Selectivity was 
assessed as analyte response in blank deionised water (n= 3). Freeze/thaw stability was 
determined by freezing (-20 °C) and thawing (ambient temperature) standard samples 
(5 pg/mL, 20 pg/mL, and 100 pg/mL, n= 6) for three cycles [150]. Bench top stability was 
assessed over 8 hours by leaving the standard samples (5 pg/mL, 20 pg/mL and 100 pg/mL, 
n= 6) on the bench top at ambient temperature (20 to 25 °C). Sample storage stability was 
investigated using the subjects’ urine at the NNAL levels of 50 pg/mL, 120 pg/mL, and 
300 pg/mL (n= 6) measured at baseline and after storage in a freezer (-20 °C) for a duration 
of one month. 
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4.5 Extraction development 
4.5.1 DLLME assay development  
Blank urine, collected from a non-smoker without any passive exposure to tobacco smoke in 
the previous 48 hours, was adjusted to pH 10 using ammonia solution. An aliquot (1 mL) was 
spiked with 40 µL of NNAL standard solution at concentration of 500 pg/mL (prepared from 
NNAL working standard solution at 5 ng/mL) and 20 µL of internal standard solution 
(5 ng/mL) equivalent to 20 pg/mL of NNAL and 100 pg/mL of NNAL-d3 in urine 
respectively. Disperser solvent (300 µL; methanol, ethanol, or acetone) containing 50 µL of 
DCM (extraction solvent) was rapidly added into the urine solution using a micropipette. The 
sample tube was gently shaken for 1 min by hand to combine the organic solvents and 
aqueous solution. Then the capped test tube was put in an ultra-sound bath for 10 min. After 
sonication, a miscible solution with fine droplets was formed. The solution was centrifuge at 
5000 rpm for 5 min and the organic phase containing analytes was separated on the bottom of 
the aqueous phase. The organic phase was transferred with a micro pipette into a glass vial 
and evaporated to near dryness using nitrogen gas for 25 min. The analyte was reconstituted 
with 100 µL of deionised water before analysing NNAL levels using UPLC-MS/MS. 
 
4.5.2 DLLME based on solidification of floating organic drop (DLLME-SFO) assay 
development 
Based on the concept of DLLME, 1-undecanol was used as an extraction solvent in the 
DLLME-SOF assay and acetonitrile was used as a disperser solvent. Similarly, blank urine 
was spiked with 40 µL of NNAL standard solution (500 pg/mL) and 20 µL of internal 
standard solution (5 ng/mL) equivalent to 20 pg/mL of NNAL and 100 pg/mL of NNAL-d3 in 
urine respectively. Acetonitrile (300 µL) containing 50 µL of 1-undecanol was added into the 
urine solution. The tube was gently shaken for 1 minute by hand and kept in an ultra-sound 
bath for 10 min. Miscible solution with fine droplets combined analyte was formed after 
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sonication. The solution was centrifuged at 5000 rpm for 5 min; the supernatant organic 
phase was separated on the top of the aqueous phase. Then the test tube was placed in an ice 
bath for a few minutes to solidify the organic phase. The solidified organic phase was 
transferred into a new test tube and thawed at ambient temperature automatically. 
Acetonitrile (100 µL) was added into the organic solution to assist the nitrogen gas induced 
evaporation. In addition, different evaporation temperatures (25 °C, 32 °C, and 45 °C) and 
different evaporation durations (15 min, 25 min, and even up to 40 min) were attempted. 
 
4.5.3 Derivatisation of NNAL 
Blank urine sample was centrifuged at 5000 rpm for 5 min and hexane was then added to 
remove non-polar interferences in urine. An aliquot of urine sample (1 mL) was spiked with 
standard and internal standard solutions and mixed well. Ethanol-pyridine (300 µL, 4:1 v/v), 
a disperser solvent, was added in the sample, and ethyl chlorofomate (20 µL) was added as 
derivation solvent. After vortexing for 3 min, diethyl ether (1 mL) was added and the solution 
was gently shaken at 175 rpm (Shaker, Paton Scientific, Australia) for 15 min to pause the 
derivation reaction. Then the solution was centrifuged at 2000 g for 10 min. The supernatant 
phase (ethereal phase) was transferred into a glass vial and evaporated with nitrogen gas at 
25 °C to near dryness. The analyte was then reconstituted in 100 µL of deionised water and 
transferred into an insert for NNAL analysis.  
 
4.5.4 Solid-phase extraction (SPE) 
Solid phase extraction cartridges (OASIS HLB cartridge, Waters, NSW, Australia) were 
conditioned with two 1 mL aliquots of acetonitrile, and washed with two 1 mL aliquots of 
deionised water. The conditioned cartridges were not allowed to dry out before the addition 
of the sample. An aliquot of blank urine sample (1 mL), spiked with standard (40 µL, 
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500 pg/mL), was added into the cartridge and passed through the cartridge, one mL of 
deionised water was used to wash the cartridge. After the aqueous phase was washed out of 
the cartridge, two aliquots (0.75 mL) of acetonitrile were added to elute the analytes from the 
cartridge and the elution was collected in 1.5 mL EppendorfÒ tube. The elution was 
centrifuged at 5000 rpm for 5 min and transferred into a glass vial and evaporated with 
nitrogen gas at 25 °C to near dryness. The analytes were reconstituted with deionised water 
(80 µL) and spiked with internal standard (20 µL, 5 ng/mL) for NNAL analysis.  
 
4.5.5 Liquid-liquid extraction 
Blank urine was adjusted to pH 7, 10, or 12 using ammonia buffer. The samples were then 
spiked with 40 µL of working standard solution (5 ng/mL) and 20 µL of internal standard 
solution (5 ng/mL). Extraction solvent (ethyl acetate, hexane, or toluene) and disperser 
solvent (acetonitrile, 1 mL) were added to urine samples of each urinary pH, and with 
different urine/extraction solvent volume ratios (v/v). The tube containing spiked urine and 
solvents was shaken for 1 min by hand and vortexed for 3 min to ensure proper mixing of 
urine and solvents. Then the solution was kept for 5 min at ambient temperature to allow the 
separation of the solvent phase and aqueous phase, and then all the samples were centrifuged 
at 2000 g for 8 min. The supernatant organic phase was transferred into a glass vial. A 
duplicated extraction process was applied to all the samples, aimed to determine whether a 
repeat extraction procedure can improve the extraction efficacy. The supernatant organic 
phase was evaporated using nitrogen gas for 15 min to near dryness, then reconstituted with 
100 µL of the deionised water before analysing for NNAL levels using UPLC-MS/MS. 
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4.6 Results and discussion 
The developed extraction assays and recovery of NNAL in urine samples are summarised in 
Table 4.2. 
 
4.6.1 UPLC-MS/MS performance 
MS was set to scan a specific mass range of analytes. The full scan analysis of mass can 
assist to select the appropriate ion for quantification and qualification of analytes. The MS 
was operated in positive electrospray ionisation mode with MRM. At the beginning, with the 
selected MRM transition, m/z 210.1→ 149.1 (NNAL) and m/z 213.1→ 149.1 (NNAL-d3), the 
chromatogram peak area of both NNAL and NNAL-d3 was embedded with the background 
noise signals, which prevented use for quantitation, possibly due to the urinary matrix effects. 
Therefore, different MRM transitions were tested to find the optimal MRM transition for 
quantitation of NNAL. The appropriate MRM transitions monitored for NNAL quantitation 
were m/z 210.1→180.1 (NNAL), m/z 213.1→183.1 (NNAL-d3). The chromatograms for 
NNAL and NNAL-d3, extracted from blank urine samples, are shown in Figure 4.1. NNAL 
and NNAL-d3 eluted at 3.62 and 3.61 min respectively. The final UPLC-MS/MS assay 
demonstrated satisfactory performance, meeting the acceptance criteria.  
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Figure 4.1 Representative UPLC-MS/MS chromatograms of NNAL and NNAL-d3 in blank urine 
sample with a concentration of NNAL of 20 pg/mL 
 
4.6.2 Urinary pH 
NNAL has two calculated pKas, 13.5 and 5.4 [calculated using Advanced Chemistry 
Development (ACD/Labs) Software V11.02, referenced from Scifinder]. In high pH or low 
pH solution, NNAL is mostly in the ionised state. The recovery of NNAL at urinary pH 7 
was greater than at both higher urinary pH 10 and pH 12. Therefore, all the urine samples 
were adjusted to pH 7 for assay development.  
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4.6.3 DLLME assay performance  
In general, there are several requirements to perform satisfactory extraction of an analyte 
using DLLME. Firstly, the extraction solvent should have low solubility in the aqueous phase 
and a greater density than water to facilitate phase separation by centrifugation. DCM met the 
requirements of an extraction solvent in the DLLME assay. The second requirement of 
DLLME is that the disperser solvent should be miscible with both the extraction solvent and 
the aqueous phase. The disperser solvent is used to assist the dispersion of an organic 
extraction solvent into an aqueous sample and to further obtain a high efficient extraction. 
Therefore, methanol, ethanol, and acetone were used for this purpose. As shown in Figure 4.2, 
a miscible solution was formed with both ethanol and acetone. In particular, ethanol formed a 
finely miscible solution. The formation of the miscible solution was due to the co-solvency of 
the disperser solvent with the extraction solvent and aqueous phase. Ethanol introduced a 
greater dispersion of DCM into aqueous phase than acetone. In contrast, methanol did not 
form a miscible solution. This may have been due to the hydrophilic properties of methanol 
that cannot be miscible with the aqueous phase. Therefore, ethanol was chosen as a disperser 
solvent. Ultra-sound bath sonication was used to improve extraction efficiency in DLLME 
assay as previously reported [151]. Different extraction times were applied (3 min, 5 min, and 
10 min). A fine miscible solution was formed with 10 min ultra-sound bath sonication. Hence, 
DCM and ethanol were used with ultra-sound bath sonication to extract spiked NNAL from 
blank urine samples. However, the recovery of NNAL was low, only about ~25%, which was 
not efficient, especially given the low biological levels.  	 	
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Figure 4.2 DLLME assay development. DCM was used as an extraction solvent; ethanol (left-
side), acetone (middle) or methanol (right-side) was used as a disperser solvent. After 10 min 
sonication, miscible solutions were formed with ethanol and acetone but not with methanol 
 
4.6.4 DLLME-SFO assay performance 
A solution was required to overcome the issue of low recovery of NNAL in the DLLME 
sample preparation. Generally, organic solvents used in DLLME are toxic and limited to 
carcinogenic chlorinated solvents, such as 1,1,1-trichloroethane and tetrachloroethane. The 
extraction phase normally settles to the bottom of the centrifuge tube after centrifugation 
because of the higher density of chlorinated solvent than water. As an alternative, the concept 
of DLLME based on solidification of a floating organic droplet (SFO) has been developed 
[143, 147, 148]. Solidification of the floating organic droplet means that the extraction 
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solvent should have a melting point close to or below room temperature and the density must 
be lower than that of water. 1-Undecanol, a long-chained fatty alcohol that has a melting 
point at 11 °C and a lower density than water, will float on the top of the aqueous phase, 
solidify below 11 °C and melt at ambient temperature. Theoretically, 1-undecanol phase 
would be easier to transfer into a glass vial compared to DCM, which required a glass needle 
to transfer it from the bottom of the centrifuge tube. Thus, we developed an DLLME-SFO 
assay to extract NNAL from urine samples by using 1-undecanol as extraction solvent.  
 
One problematic issue for 1-undecanol is that it is highly lipophilic with a boiling 
point of 243 °C, and therefore difficult to evaporate it directly with nitrogen gas. Mixing 1-
undecanol with other lipophilic and hydrophilic solvents was used to assist the evaporation 
process. Acetonitrile, toluene, hexane, ethyl acetate, DCM, acetone, and methanol were 
added to the 1-undecanol containing extracted NNAL to identify which one of the solvents 
could assist the evaporation of 1-undecanol. Unfortunately, even the most lipophilic solvent – 
hexane – did not assist with the evaporation of 1-undecanol. The high temperature and long 
evaporation duration had the potential to lose the analytes, either through chemical 
decomposition or evaporative loss. The UPLC column conditions were also not suitable for 
analysis by directly injecting 1-undecanol as the extraction solvent. In previously reported 
study, UPLC column used for direct injection of 1-undecanol analysis was Agilent Tc C18 
column (4.6 ´ 150 ´ 5 micron particles) and the mobile phase was methanol and water [143]. 
The UPLC column used in our assay was BEH C18 column (2.1 ´ 100 mm ´ 1.7 micron 
particles), which was narrower than the reported UPLC column. Furthermore, the mobile 
phase used in our assay was consisted of 0.4% ammonia and acetonitrile, which was more 
lipophilic than the one used in the reported study (methanol and water). The UPLC column 
conditions were suitable for all the chemical and biological analysis in our project, and it was 
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deemed not advisable to change the column conditions. Therefore, the two new extraction 
methods, DLLME and DLLME-SFO, were not suitable for NNAL analysis using our 
analytical conditions.   
 
4.6.5 Derivatisation of NNAL  
Derivatisation techniques using ethyl chloroformate to form alkoxycarbonyl alky esters have 
been used in urine matrices. In theory, NNAL would be amenable to this reaction through the 
butanol functionality. Ethylchloroformate techniques have been successfully applied to 
serotonin and bisphenol A derivatisation previously [152]. In addition, the ethylchloroformate 
derivatives are often much more sensitive to analysis by UPLC-MS/MS than the native 
analytes. Hence, we developed an ethylcholroformate derivatisation technique to determine 
NNAL level in urine. There was a spectrum signal observed at m/z 399, however, the signal 
was not an NNAL derivative, but possibly a by-product of the derivatisation reaction. 
Therefore, the derivatisation technique was also not suitable for NNAL analysis. 
 
4.6.6 SPE assay performance 
In previously reported NNAL assays, SPE assay has often been utilised to extract NNAL 
from urine samples [124, 141]. The extraction procedures were complex, including using 
multiple extraction solvents and multiple types of SPE columns in one study. Compared to 
those reported assays, our assay aimed to simplify the extraction procedure, only using one 
extraction solvent (acetonitrile) and one type of SPE cartridge. However, the matrix 
interference from urine resulted in the NNAL signals being embedded with the 
chromatographic background signals. The simplified SPE was not suitable for NNAL 
extraction in urine samples. 
 
  Chapter 4 
	 62	
4.6.7 Liquid-liquid extraction assay performance 
Finally, a simple liquid-liquid extraction assay was developed, based on the recovery of 
NNAL from spiked blank urine samples, by adjusting urinary pH, extraction solvent and 
urine/extraction solvent volume ratio (Table 4.3). There was no difference in recovery with or 
without disperser solvent. It was found that the recovery of NNAL at urinary pH 7 was 
greater than at pH 10 and 12, due to the pKas of NNAL. Recovery also increased with larger 
extraction volumes of urine (2 mL) and extraction solvent (v/v, 1:1). Duplicate extractions 
also improved the recovery of NNAL from urine samples as expected, due to an increase in 
extractive capacity. In addition, different centrifuge durations were applied (5 min, 8 min, 
and 10 min). The results showed that clear separation was obtained with 8 min centrifugation.  
 
The NNAL standard calibration curve was linear over the range of 1 pg/mL to 
400 pg/mL with an r2= 0.9996 (Figure 4.3). Intra-day accuracy was 3.7%, 3.7% and 3.6% 
and precision was 11.3%, 5.1% and 5.3% at 5 pg/mL, 20 pg/mL and 100 pg/mL levels 
respectively. The LoD was 0.95 pg/mL and LLoQ was 3.2 pg/mL. Freeze/thaw stability 
results were within 15% and bench top accuracy was within 10% at 5 pg/mL, 20 pg/mL and 
100 pg/mL respectively. Loss after one month of sample storage was 8-15%. Carry over and 
selectivity were lower than LoD and less than 5% of LLoQ.   	 	
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Table 4.3 Recovery of NNAL from spiked urine samples during liquid-liquid extraction 
development 
 
 Recovery % 
 Mean SD 
pH (ethyl acetate; v: v= 1:1)   
7 50 21 
10 20 0.23 
12 10 0.16 
Extraction solvent (pH 7; v: v= 1:1)   
Ethyl acetate 55 12 
Hexane -  
Toluene -  
Volume ratio a (pH 7; ethyl acetate)   
1:1 28 0.90 
1:1×2 b 64 16 
2:2 65 15 
 
Note: 20 pg/mL of NNAL standard and 100 pg/mL of NNAL-d3 was spiked into the blank urine; urinary 
pH was adjusted with ammonia solution; a volume ratio= urine/extraction solvent (v/v); b= duplicate 
extraction. 	 	
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Figure 4.3 The NNAL standard calibration curve was linear over the range of 1 pg/mL to 
400 pg/mL with an r2= 0.9996. Error bar represent the standard deviation 
 
This liquid-liquid assay is an improvement over existing SPE-based methods in that it 
is substantially less complicated while maintaining adequate sensitivity. The main extraction 
procedures are summarised in Table 4.4. The simple but sensitive NNAL assay we developed 
will be useful for studying the effectiveness of tobacco harm reduction strategies. 	  
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4.7 Conclusion 
Based on a comparison between different extraction assays, liquid-liquid extraction with 
UPLC-MS/MS measurement is a convenient and sensitive approach to measuring low levels 
of NNAL in urine as a biological marker of NNK exposure. This method of determination 
can be used to assess tobacco-related exposure and the effectiveness of smoking reduction 
harm minimisation strategies.  
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Chapter 5: Application of Assay for 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) in Urine for the Assessment of 
Tobacco-related Harm 
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5.1 Background 
Smoking has been widely known to be associated with adverse health effects. Cigarette 
smoking is the leading cause of preventable mortality and morbidity. Millions of people 
worldwide die from tobacco-related diseases each year [1].  
 
While complete cessation of smoking is the preferred outcome, increasingly 
researchers and policy makers are exploring harm minimisation approaches, for example, 
smoking reduction using alternate forms of nicotine delivery to curb tobacco-related harms. 
A key argument supporting harm minimisation strategies is that by reducing cigarette 
smoking, we reduce exposure to tobacco toxins and, hence, subsequent tobacco-related 
morbidity and mortality [69]. The reduction can be determined by monitoring smoking 
patterns, such as cigarettes per day, withdrawal severity, and craving for cigarettes. 
Furthermore, an evaluation of such strategies necessitates measuring the level of hazardous 
tobacco-related chemicals present in biological samples, such as plasma and urine.  
 
As introduced in Chapter 4, NNK is a known lung carcinogen presented in both 
unburned tobacco and cigarette smoke [121, 139]. And its major metabolite NNAL is 
considered an effective biomarker for exposure to tobacco-related harm [121]. It has also 
been proposed that the ratio of NNAL-glucuronide to total NNAL could be a potential 
biomarker [153] with rapid metabolism to the glucuronide inferring faster detoxification 
[154]. However, the importance of this ratio remains unclear, with different findings between 
studies and ethnic groups [124, 126, 154, 155]. Proper validation of analytical methods 
determining total (free + conjugated) NNAL remains difficult. These methods rely on 
enzymatic cleavage of the NNAL-glucuronide to yield the aglycone and then measuring the 
total NNAL after hydrolysis. This approach can lead to loss of accuracy and precision [156]. 
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A simple but sensitive bioassay of NNAL using liquid-liquid extraction and UPLC-
MS/MS was developed (in Chapter 4) and applied to smokers’ urine to assess tobacco 
exposure, investigating both free and total NNAL levels. 
 
5.2 Materials 
5.2.1 Reagents 
The NNAL standard, NNAL-d3 and extraction solvents were the same as described in section 
4.3.1. b-Glucuronidase (type IX-A, Escherichia coli) and phosphate buffered saline tablets 
were purchased from Sigma-Aldrich (NSW, Australia). 
 
5.2.2 UPLC Instrumentation and analytical condition 
UPLC-MS/MS system analytical conditions were the same as described in section 3.3.3 and 
3.3.4. The MRM transitions monitored for quantitation were m/z 210.1→180.1 (NNAL), m/z 
213.1→183.1 (NNAL-d3). Cone voltage was optimised for each MRM transition at 24 V. 
Dwell time for each transition was 78 msec. 
 
5.2.3 Preparation of calibration solutions 
A standard stock solution of NNAL (200 µg/mL) was prepared by dissolving 10 mg of 
NNAL standard in 50 mL of methanol in a volumetric flask. Similarly, NNAL-d3 stock 
solution (100 µg/mL) was prepared by dissolving 1 mg of NNAL-d3 in 10 mL of methanol in 
a volumetric flask. The stock solutions were stored in a refrigerator at 4 °C. NNAL working 
standard solution (5 ng/mL) and NNAL-d3 internal standard solution (5 ng/mL) were freshly 
prepared from the stock solutions by dilution with deionised water. Calibration standard 
solutions were prepared by spiking NNAL working standard solution in blank urine over an 
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ascending concentration range of 1 to 400 pg/mL, and spiked with 100 pg/mL of internal 
standard. 
 
5.2.4 Assay performance 
Assay performance validation of accuracy, precision, LoD, LLoQ and sample stability was 
prepared in blank urine and processed as described in section 4.4.3. 
 
5.3 Application among community samples of cigarette smokers 
Urine samples (n= 48 samples) were collected from current smokers (n= 24) as part of a 
larger smoking cessation study. Participants were current smokers who were willing to use 
either varenicline (0.5 mg and 1 mg, Champix®, Pfizer Australia Pty Ltd) or nicotine patch 
(21 mg/24 hr, Nicabate®, GlaxoSmithKline Australia Pty Ltd) as part of a quit attempt. 
Participants provided a urine sample at baseline (prior to starting their quit attempt and during 
ad lib smoking) and a second sample four weeks after a target quit day. Additional 
information around the study protocol has been published elsewhere [157].  This study was 
approved by the Tasmania Health and Medical Human Research Ethics Committee. 
 
5.4 Smokers’ urine sample preparation 
5.4.1 Free NNAL analysis 
Smokers’ urine samples were stored at -20 °C prior to analysis. Following thawing at ambient 
temperature, the samples were centrifuged at 2000 g for 5 min. For free NNAL analysis, 
aliquots of each urine sample (adjusted to pH 7 with ammonia solution, 2 mL) were spiked 
with 40 µL of NNAL-d3 (5 ng/mL) equivalent to 100 pg/mL of urine and mixed. An equal 
volume of ethyl acetate (2 mL) was then added to the urine solution. The tube containing 
spiked urine and solvents was shaken for 1 min by hand and vortexed for 3 min to mix urine 
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and solvents. The solution was kept for 5 min at ambient temperature to allow the separation 
of the solvent phase and aqueous phase, and then all the samples were centrifuged at 2000 g 
for 8 min. The supernatant organic phase was transferred into a glass vial. The extraction 
process was duplicated to all the samples. The supernatant organic phase was evaporated to 
near dryness by using nitrogen gas. All the samples were then reconstituted with 100 µL of 
deionised water before using UPLC-MS/MS to determine NNAL levels. 
 
5.4.2 Total NNAL analysis  
The total level (free NNAL + glucuronide conjugate) of NNAL was determined by enzymatic 
hydrolysis of urine based on methods employed previously [124, 126, 155]. The enzyme 
solution was prepared by dissolving b-glucuronidase Type IX-A enzyme in phosphate buffer 
saline (pH 7.4, 10 mM phosphate buffer, 2.7 mM potassium chloride and 137 mM sodium 
chloride) equivalent to an enzyme activity of 40,000 units/mL. Aliquots of each urine sample 
(2 mL) were spiked with 40 µL of NNAL-d3 (5 ng/mL) equivalent to 100 pg/mL of urine and 
mixed. The urine solutions were treated with 100 µL of b-glucuronidase enzyme solution 
equivalent to 2000 units/mL of urine. The samples were vortexed and placed in an incubator 
at 37 °C for 20 hours in the dark. The hydrolysed urine samples then used the same extraction 
process as free NNAL analysis. The calibration standard samples were processed using the 
same extraction procedure. 
 
5.5 Results and discussion 
5.5.1 Assay performance 
The assay validation parameters including precision, accuracy, LoD and LLoQ met the 
acceptance criteria. A representative chromatogram of a smoker’s urine sample with a level 
of free NNAL 45 pg/ml (at the lower range of NNAL samples) is shown in Figure 5.1. The 
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average recovery of free NNAL extracted from the smokers’ urine samples was 59.6% ± 23.5 
(mean ± SD).  
 
 
 
Figure 5.1 Representative UPLC-MS/MS chromatograms of free (unconjugated) NNAL and 
NNAL-d3 from a smoker’s urine sample with a concentration of NNAL of 45 pg/mL  	  
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5.5.2 NNAL levels in smokers’ urine 
The average free NNAL level in the smokers’ samples (n= 24) prior to starting their quit 
attempt was 193.52 ± 158.17 pg/mL (mean ± SD); this fell to 64.49 ± 77.59 pg/mL four 
weeks after the quit attempt (p<.002; Figure 5.2). As expected, NNAL levels were 
significantly reduced following the quit attempt; this supports the use of NNAL as a 
biomarker of tobacco-related exposure and harm minimisation. Other studies have 
determined the total NNAL level (free + glucuronide) in urine samples [115, 126, 155]. 
 
 
 
Figure 5.2 The box-whisker plot represents the range of NNAL levels measured from smokers’ 
urine samples. The bottom and top of the box represent the first and third quartiles of NNAL 
levels; the band inside the box represents the median of NNAL levels; the ends of the whiskers 
represent the standard deviation above and below the mean of NNAL levels  
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Total NNAL levels were measured using the β-glucuronidase enzyme to hydrolyse 
NNAL-glucuronide conjugates to free NNAL aglycone. However, it was found that under 
previously reported standard hydrolysis conditions [124, 126, 155], the ratio of total NNAL 
to free NNAL was <=1 for some urine samples in our sample population (Figure 5.3). 
Enzymatic hydrolysis was clearly unreliable and there was a potential for significant loss of 
either free NNAL and NNAL aglycone. Figure 5.4 shows the loss of NNAL analyte from a 
smokers’ urine sample following enzymatic hydrolysis. Possible mechanisms for this loss 
may be that the aglycone is unstable in the hydrolytic conditions of the standard procedure, or 
binds non-specifically to the β -glucuronidase or matrix [156]. Hence, based on our findings, 
indirect glucuronidase hydrolysis approach is not recommended. It is worth noting that three 
recent studies [124, 126, 155] have not adequately undertaken validation of measuring NNAL 
aglycone, but rather inferred validation using results from free NNAL analysis or repeat 
hydrolysis of the same samples. Proper validation of indirect methods such as β –
glucuronidase hydrolysis to measure total NNAL (free + glucuronide) or conjugated NNAL 
by difference (as used in the detoxification ratio) should utilise NNAL-glucuronide standards.  	  
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Figure 5.3 Ratio of total NNAL (aglycone measured after hydrolysis) to free NNAL, where a 
ratio <= 1 indicates loss of NNAL aglycone caused by the β-glucuronidase hydrolysis 
procedure 
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Figure 5.4 UPLC-MS/MS chromatogram of a representative urine sample before (A; free NNAL 
at 256 pg/mL) and after (B) β-glucuronidase hydrolysis under standard conditions, showing 
loss of NNAL aglycone to below method detection limit following hydrolysis 
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Our previous study demonstrated, to determine total levels of metabolites, indirect 
methods of measuring glucuronide metabolites using β-glucuronidase hydrolytic cleavage 
were unreliable for metabolites of nicotine [128]. Proper validation of indirect methods such 
as β-glucuronidase hydrolysis to measure total NNAL (free + glucuronide) or conjugated 
NNAL by difference (as used in the detoxification ratio) should utilise NNAL-glucuronide 
standards. 
 
5.6 Conclusion 
In summary, NNAL can be accurately quantified with a single ethyl acetate extraction. This 
new assay is an improvement over existing SPE-based methods in that it is substantially less 
complicated while maintaining adequate sensitivity. It is a straightforward approach to 
measuring the NNAL level in smokers’ urine. Application of the assay was successfully used 
to assess tobacco-related harm exposure and the effectiveness of smoking reduction harm 
minimisation strategies. Enzymatic hydrolysis of NNAL-glucuronide as a technique for 
measuring the aglycone is not recommended.  
 
	
 
 
 
 
 
 
Chapter 6: The Effect of Varenicline and 
Nicotine Patch on Smoking Rate and 
Satisfaction with Smoking: An examination of 
the mechanism of action of two pre-quit 
pharmacotherapies 
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6.1 Background 
Every year, millions of people die from tobacco smoking and suffer from tobacco-related 
diseases [1, 158]. After not commencing smoking in the first place, encouraging successful 
cessation is the most effective strategy for reducing smoking-related harm [9]. Currently, 
smokers can choose from a number of efficacious, if clearly imperfect, cessation medications 
and methods to aid a quit attempt [66]. Smoking cessation medications, chiefly nicotine 
replacement therapies and varenicline, are considered first line treatments [159, 160] for 
smokers wishing to quit. 
 
Until relatively recently, smokers attempting to quit with nicotine replacement 
therapies were restricted to abrupt cessation attempts. That is, they were advised to stop 
smoking entirely prior to stating their quit attempt. More recently, some guidelines for 
smoking cessation (e.g., in the U.K.[70]) have made recommendations to allow smokers to 
use medications – typically nicotine replacement – to aid gradual reduction prior to a quit 
attempt. Reduce to quit approaches are underpinned by evidence that smoking reduction prior 
to quitting improves a smoker’s odds of successful cessation [29, 31, 34, 47, 161]. There is 
also evidence that successful smoking reduction actually promotes interest in quitting [33], 
and a suggestion that it is a useful treatment for smokers who are currently disinterested in 
complete cessation [9].  
 
Nicotine patch is the mostly widely used form of Nicotine Replacement Therapy 
(NRT) and was originally designed to be initiated on a patient’s quit day [162, 163]. In recent 
years, however, nicotine patch has been used by starting treatment 1-2 weeks prior to quitting 
(known as preloading [74]), and followed by a standard post-quit patch regime. Our group 
has reported that pre-quit nicotine patch reduced the satisfaction with smoking and daily 
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cigarette smoked during the pre-quit period, and theorised that the reduced satisfaction might 
drive the smoking reduction and, in turn, cessation [133]. This finding is in line with earlier 
studies which reported that smokers rate smoking less satisfying while they were wearing 
nicotine patch [164, 165]. However, our study was a small (n= 61), single-group feasibility 
study and did not have a control group, rendering us unable to determine whether pre-quit 
patch treatment might be a causal factor in the reduction of satisfaction and daily smoking 
rate during the pre-quit period as opposed to these variables simply naturally dropping in the 
lead up to a quit attempt. To overcome this limitation, this current study was designed to 
include a control group of participants who obtained nicotine patch treatment on quit day. In 
addition, varenicline is the newest pharmacotherapy treatment and has been found more 
effective than a single type of NRT [55]. Varenicline has been reviewed in literature that it 
can increase the sustained abstinence rates in long-term smoking cessation [166]. The use of 
varenicline starts 1-2 weeks prior to quit day, similar to the pre-quit patch regime. The 
efficacy of varenicline might also be mediated via the reduction in satisfaction gained from 
smoking, but similarly to pre-quit patch treatment, this mechanism has not explicitly been 
tested before [57]. Understanding how these two pre-quit treatments impact the reduction of 
smoking, and whether the type of pre-quit treatment makes any difference on satisfaction 
with smoking during the pre-quit period may help to better tailor treatment for an individual. 
 
The study was designed as a three-group, randomised, open-label study [157]. The 
primary objective of this study was to examine the effects of the pre-quit use of varenicline 
and nicotine patch on the daily smoking rate and satisfaction with smoking, and test the 
relationship between these variables during the two weeks leading up to a quit attempt. 
Participants were randomised to either a standard patch group that started patch treatment 
from an assigned target quit day, or one of two pre-quit treatments groups, which receive 
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either pre-quit patch or varenicline two weeks prior to a quit day, all followed by ten weeks 
of post-quit treatment. We hypothesised that 1) satisfaction with smoking would decline 
during the two week pre-quit period for smokers treated with patch or varenicline (compared 
to smokers in the standard patch group); 2) the smoking rate would decline during the two 
week pre-quit period for smokers treated with patch or varenicline (compared to smokers in 
the standard patch group); and 3) satisfaction with smoking would mediate the effect of pre-
quit treatment on smoking reduction during the two week pre-quit period. Finally, we 
examined differences in smoking reduction and satisfaction among the treatment groups. We 
mainly focused on effectiveness of pre-quit treatment on reduction of smoking rate and 
satisfaction with smoking in Chapter 6. Adding biological measures will confuse the main 
purpose of this chapter. In addition, the biological measures were reported in Chapter 5, page 
73. Therefore, the biological measures were not included in Chapter 6. 	
6.2 Methodology 
6.2.1 Participants 
Participants who were interested in quitting were recruited mainly through advertisements on 
social media [167, 168] and local newspapers. Screening established eligibility according to 
the inclusion criteria: Being 18 years of age or older; current daily smoking ≥ 10 cigarettes 
per day (CPD) for at least the last 3 years; having a high motivation to quit smoking (defined 
as scoring ≥ 75 on a 100 point motivation scale; [169]); and willing to use either patch or 
varenicline as part of a quit attempt. Participants were excluded if they were currently 
enrolled in a smoking cessation trial, or had been within the past three months or were 
unsuitable for treatment with either patches or varenicline. The study was approved by the 
Tasmanian Health and Medical Human Research Ethics Committee (H0013619). 
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6.2.2 Treatments 
Participants were randomised to two pre-quit groups (nicotine patch or varenicline) or to a 
standard patch group without pre-quit treatment. Participants in the pre-quit groups were 
provided either nicotine patch (21mg/24 hr) or varenicline for two weeks prior to their target 
quit day. Participants in the standard patch group started patch treatment on their target quit 
day and did not receive any treatment during the pre-quit period. 
 
All groups then received ten weeks of post-quit treatment. Participants in the two 
patch groups remained on the same dose (21mg/24 hr) for ten weeks following their assigned 
quit day; the dose was not titrated downwards over the course of the study [170]. With 
varenicline treatment, participants received 1 mg twice per day following a one-week titration 
period (0.5 mg once per day for three days, followed by 0.5 mg twice per day for four days). 
Participants were asked about the treatment use, including frequency of use and adverse 
events, at each study visit. 
 
6.3 Procedures 
6.3.1 Baseline visit.  
The detailed study procedures can be accessed in our published study protocol (Appendix I) 
[157]. Briefly, participants completed five study visits over the course of the study: 
Enrolment visit (Day -17), Treatment assignment visit (Day -14), Quit day visit (Day 1), 
Follow-up visit (Day 14), Final visit (Day 28). At the Enrolment visit, participants were 
firstly given a detailed overview of the study requirements and asked to provide written 
informed consent. Participants were then randomised to the treatment group and assigned a 
target quit day. Participants were asked to complete baseline data collection during the 
Enrolment visit. This consisted of demographic (e.g., age, gender, ethnicity etc.), smoking 
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history characteristics (e.g., cigarettes per day [CPD], years smoked, interest in quitting etc.), 
and information about satisfaction with smoking (modified Cigarette Evaluation 
Questionnaire [mCEQ] [171]). Next, participants were asked to complete a 14-day timeline 
follow-back (TLFB) [172] and to provide two exhaled carbon monoxide (CO) samples. Both 
the TLFB questionnaire and CO measurements were repeated at all subsequent study visits.  
 
6.3.2 Ecological Momentary Assessment (EMA) data collection 
From enrolment until two weeks after their quit day (approximately 28-days of monitoring in 
total) participants were required to monitor their smoking behaviour, affect and activities in 
real-time conditions using a smartphone running study-specific software [173]. The EMA 
monitoring procedures were modelled on previous smoking studies [174, 175]. Participants 
were required to carry the device with them at all times and to indicate (by tapping a button) 
each time they smoked a cigarette; ~4-5 cigarettes per day were randomly selected for 
assessment during which participants were asked to report on their current affects, location 
and activities. Along with smoking assessment, participants completed ~4-5 randomly-timed 
non-smoking assessments (“random prompts), each day. These assessments largely paralleled 
those administered during smoking assessments but also included a question on satisfaction 
with the most recently smoked cigarette (rated on a 0-100 point scale). Participants were 
required to complete an evening assessment between 7 pm and midnight. During this 
assessment, participants reported on daily mood and satisfaction with smoking (rated on a 0-
100 point scale), among other items (see [157] for further details). EMA data was 
downloaded and checked at each study visit with additional training provided when 
compliance with monitoring was less than 100% [174]. 
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6.4 Data cleaning and analytic plan 
To explore the study hypotheses, we used CPD based on TLFB reports collected at study 
visits; daily satisfaction with smoking was taken from the evening reports where available, 
and from the mean of that day’s random assessments if random prompt responses were 
available when an evening report was not. We also analysed the data using real-time CPD 
counts and found similar results (data not presented).  
 
The effects of pre-quit treatment on both satisfaction with smoking and the number of 
CPD were assessed using linear mixed models to account for the multi-level structure of the 
data (repeated measures on individuals over time). The models were fitted using Stata 
statistical software (Stata 12.1). Random intercepts were incorporated into the models to 
represent individual differences in CPD and satisfaction at the start of the pre-quit period. An 
interaction of treatment group by time was included in the models to assess the differences in 
mean outcome trajectories in the three treatment groups over time. Random intercept models 
incorporating squared and cubic trends for time and their respective group by time 
interactions were compared with the simpler random intercept models with a linear trend for 
time and a group by time interaction. In both cases the linear time trend was a better fit. The 
fit of a random slopes model was then evaluated. For both CPD and satisfaction, a model 
including random slopes was found to be a better fit than the simple random intercepts model. 
The final models thus incorporated both random intercepts and random slopes, a linear trend 
for time and an interaction of time by the treatment group. 
 
To assess the extent to which between-person difference in satisfaction mediated the 
effect of treatment on cigarettes smoked per day, the effect of treatment on CPD was 
modelled with and without adjustment for satisfaction. This allowed us firstly to assess both 
  Chapter 6	
	 85	
the direct effect of treatment on CPD, controlling for satisfaction, and the total effect of 
treatment on CPD, including the effect of satisfaction.  This is a so-called lower level or 
2→1→1 mediation [176], where the effect of a level 2 predictor (treatment group) on a level 
1 outcome (smoking rate) is mediated by a level 1 predictor (satisfaction). Random intercepts 
and random slopes for both time and satisfaction were fitted to allow both change in CPD 
over time and change in CPD with change in satisfaction to vary across individuals. All 
covariates were grand-mean centred. As a final step, for each treatment group, the mean daily 
change in satisfaction that was associated with treatment was multiplied by the mean effect of 
a one-unit change in satisfaction on CPD, in order to determine the mean indirect effect of 
treatment on CPD, via satisfaction. To ascertain whether these indirect effects were 
significantly greater than zero, it was necessary to estimate the standard errors of the products 
of the two regression coefficients. Hayes and Preacher [177] suggest bootstrapping as the 
most reliable method of estimating variance in these parameters. However, the autoregressive 
specification for the residual correlation used in the above linear mixed models created 
problems with bootstrapping, as replacement of observations for bootstrapping resulted in 
repeated time measures within individuals. This model is unable to run with tied time 
measures for individuals. Another resampling method, the jackknife method, was therefore 
used in this analysis to estimate the standard errors: we ran the above linear mixed models 
multiple times with one subject omitted each time, and estimated the product of coefficients 
multiple times. The mean and standard deviation (SD) of the set of estimated products were 
then used to calculate the 95% confidence intervals (CI). 
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6.5 Results 
6.5.1 Demographic of participants and data reduction 
A total of 213 participants were enrolled and randomised to a treatment group (Table 6.1). 
The average participant was female (58%), Caucasian (93%), 42 years old, and smoked 19 
CPD. The three treatment groups were evenly balanced, not differing on any of the 
characteristics measured (Table 6.1). 
 
A total number of 213 participants were enrolled, but n= 30 withdrew from the study 
without providing either TLFB or EMA data during the pre-quit period. Thus, there were 183 
participants who were eligible for analysis: 60 eligible participants in the standard patch 
group, 62 in the pre-quit patch treatment group and 61 in the varenicline group. The resulting 
dataset comprised 2,562 potential participant-days of observation. Of the 183 participants, 95 
(51.9%) recorded at least some of the data on all 14 pre-quit days, and 153 (83.6%) recorded 
data on at least 7 days. The mean number of days with data recorded was M= 11.39 days per 
participant [standard deviation (SD)= 3.98]. 	 	
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Table 6.1 Demographic and smoking characteristics: overall, and by treatment group 
 
 Treatment group  
 
Standard patch 
(n= 69) 
Pre-quit patch 
(n= 72) 
Varenicline 
(n= 72) 
Total 
(n= 213) 
Age (mean, SD) 39.7 (11.1) 43.8 (13.4) 43.1 (12.2) 42.2 (12.3) 
Gender: % female (n) 50.7 (35) 63.9 (46) 59.7 (43) 58.2 (124) 
Race: % Caucasian (n) 91.3 (63) 93.1 (67) 93.1 (67) 92.5 (197) 
Post-year 12 
education: % (n) 57.4 (39) 45.1 (32) 52.8 (38) 51.7 (109) 
Employed:  % (n) 72.5 (50) 56.9 (41) 80.6 (58) 70.0 (149) 
Cigarettes per day  
(mean, SD) 
17.9 (7.0) 19.4 (9.8) 19.3 (7.0) 18.8 (8.0) 
Time to first cigarette £ 
30 min: %(n) 69.6 (48) 76.4 (55) 76.4 (55) 74.2 (158) 
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6.5.2 Reduction in CPD and satisfaction during pre-quit period 
There was a significant linear reduction of 0.34 cigarettes per day over the pre-quit period in 
the pre-quit patch group (95% CI= 0.23-0.45) and 0.39 cigarettes per day in the varenicline 
group (95% CI= 0.28-0.51) (Table 6.2; Figure 6.1). The difference in the daily reduction in 
CPD between the pre-quit patch and varenicline groups was not significant (p= 0.49). CPD 
did not change significantly over the pre-quit period in the standard patch group (mean daily 
reduction in CPD= 0.05, 95% CI= -0.07-0.17). 
 
Mean satisfaction with smoking decreased by 0.8 points per day in the pre-quit patch 
group (95% CI= 0.32-1.29) and 1.8 points per day the varenicline group (95% CI= 1.31-2.28) 
(Table 6.3, Figure 6.2). Change in satisfaction per day was significantly greater in the 
varenicline group than the pre-quit patch group (p= 0.005). Satisfaction with smoking did not 
change over the pre-quit period in the standard patch group. 	  
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Table 6.2 Daily reduction in mean cigarettes per day (CPD) for each treatment group over the 
pre-quit period: Results from linear mixed models 
 
Treatment 
group 
Daily 
reduction 
in CPD (β) 
Standard 
error 
(SE) 
95% 
Confidence 
Interval 
p1 * p2 ** p3*** 
 
Standard patch 
Pre-quit patch 
Varenicline 
 
 
0.05 
0.34 
0.39 
 
0.06 
0.06 
0.06 
 
-0.07, 0.17 
0.23, 0.45 
0.28, 0.51 
 
0.45 
<0.001 
<0.001 
 
- 
<0.001 
<0.001 
 
- 
- 
0.49 
 
*p1= p-value from Wald test of interaction coefficient estimating change in cpd over time (versus null 
hypothesis of no change). 
**p2= p-value from test of difference in change over time in respective treatment group versus 
standard patch. 
***p3= p-value from test of difference in change over time in pre-quit patch group versus Varenicline 
group. 
 
 
 
Table 6.3 Daily reduction in mean satisfaction with smoking for each treatment group over the 
pre-quit period: Results from linear mixed models 
 
Treatment 
group 
 
Daily 
reduction in 
satisfaction 
(β) 
Standard 
error 
(SE) 
95% 
Confidence 
Interval 
p1* p2** p3*** 
 
Standard patch 
Pre-quit patch 
Varenicline 
 
-0.08 
0.80 
1.80 
 
0.24 
0.25 
0.25 
 
-0.56, 0.40 
0.32, 1.29 
1.31, 2.28 
 
0.73 
0.001 
<0.001 
 
- 
0.01 
<0.001 
 
- 
- 
0.005 
 
 
*p1= p-value from Wald test of interaction coefficient estimating change in satisfaction over time (null 
hypothesis= no change over time). 
**p2= p-value from test of difference in change over time in respective treatment group versus 
standard patch (null hypothesis= no difference). 
***p3= p-value from test of difference in change over time in pre-quit patch group versus varenicline 
group (null hypothesis= no difference). 	 	
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Figure 6.1 Mean (and 95% confidence intervals) reduction in cigarettes per day (CPD) over the 
pre-quit period in each of the three treatment groups  
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Figure 6.2 Modelled reduction of satisfaction with smoking over the pre-quit period in each of 
the three treatment groups  
 
6.5.3 Relationship between treatment, satisfaction and CPD 
In the mediation analyses, we were interested in investigating the extent to which the 
association of effect of treatment on satisfaction was mediating the effect of treatment on 
CPD. Figure 6.3 shows the mediation model. The standard patch group experienced no 
significant daily reduction in satisfaction in smoking, and no significant reduction in 
cigarettes per day across the pre-quit period. In both the active treatment groups there was a 
significant direct effect of treatment on CPD, as shown by the c’1 and c’2   pathways. In the 
pre-quit patch group the direct effect was a mean daily reduction of 0.29 cigarettes per day 
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(95% CI= 0.19-0.39). In the varenicline group the direct effect was a mean daily reduction of 
0.32 cigarettes per day (95% CI= 0.22-0.43). Both active treatment groups also experienced a 
daily reduction in satisfaction with smoking, which had an additional small but significant 
effect on cigarettes smoked per day, calculated as a1*b and a2*b (an additional reduction in 
cigarettes per day of 0.014 (95% CI= 0.012-0.015) and 0.035 (95% CI= 0.033- 0.037) in the 
pre-quit patch and varenicline groups, respectively). The total daily reduction in cigarettes per 
day associated with treatment is ci= c’i+ ai*b for each group i= 0 to 2. This is 0.30 CPD in the 
pre-quit patch group and 0.36 CPD in the varenicline group. The percentage of the change in 
CPD mediated by satisfaction is 4.6% in the pre-quit patch group and 9.9% in the varenicline 
group. Note that the total daily reductions in satisfaction and CPD differ slightly from those 
described above, as the mediation analysis was restricted to subject-days for which 
satisfaction with smoking was recorded (76% of all subject-days). 
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Figure 6.3 Mediation Model. Notes: Each of the three treatments has direct effects on 
satisfaction and daily smoking rate. Satisfaction with smoking meditates daily smoking rate. 
All coefficients with subscripts are the associations of the relevant treatment with the outcome 
(in direction of arrow). Standard errors are in parentheses, 95% confidence intervals in square 
brackets. **p< 0.01; ***p< 0.001 
 
6.6 Discussion 
This study was designed to test the effect of pre-quit treatment – either with nicotine patch or 
varenicline – on smoking reduction and satisfaction with smoking. The results will help 
elucidate the potential mechanisms driving the reduction during the pre-quit period. 
Compared to standard patch, as hypothesised, there was 1) a significant reduction in 
satisfaction with smoking during the pre-quit period with both pre-quit treatments; and, 2) a 
significant reduction in CPD during the pre-quit period with both pre-quit treatments. These 
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results paralleled with our previous finding [133]. Furthermore, the results from the 
mediation analyses were consistent with the notion that the pre-quit treatments caused a 
reduction in satisfaction with smoking during the pre-quit period, which in turn resulted in 
fewer cigarettes smoked. Treatment with varenicline resulted in a greater decrease in 
satisfaction with smoking compared to pre-quit patch. This finding consistent with previous 
reported results that varenicline treatment results in greater decrease in the satisfaction than 
nicotine patches [178]. Varenicline binds with the nicotine acetylcholine (Ach) receptor, acts 
as a partial antagonist to prevent inhaled nicotine from activating the Ach receptor 
sufficiently to cause the pleasure and reward response [179]. In addition, the pre-quit 
treatments did cause a reduction effect on CPD during the pre-quit period, although the 
difference in the daily reduction in CPD between pre-quit patch and varenicline was not 
significant. Previous research has demonstrated that the pre-quit nicotine patch [180] and 
varenicline [166] reduced the satisfaction and cigarette consumption, as well as improved the 
abstinence rates.  
 
Our finding indicated that the reduction of satisfaction with smoking was observed 
with two pre-quit treatments during pre-quit period; and the declined satisfaction was 
associated with the reduction in daily smoking rate (p< 0.01). The results from the mediation 
analysis were as hypothesised: a relatively small, but significant, proportion of the total 
reduction in CPD could be attributed to the reduction of satisfaction with smoking in both 
pre-quit patch and varenicline groups. Satisfaction with smoking was hypothesised to mediate 
the effect of treatment on smoking reduction; as such, satisfaction with smoking might be a 
plausible marker of treatment response, potentially allowing for better tailoring of mediating 
mechanisms for the pre-quit treatment in smoking reduction, pre-quit treatment duration, or 
both. However, the relatively weak relationship between satisfaction and smoking reduction 
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suggest that satisfaction may not be a viable method of evaluation responsiveness to 
treatment. One previous study reported that varenicline promoted reduction in smoking rate, 
dependence and craving [57]. However, it was not further explained whether the reduction of 
smoking rate was mediated via reducing craving or dependence. Examining the relationship 
between these variable – and others – and smoking reduction may prove fruitful in the search 
for useful markers of treatment response. 
 
All participants received open-labelled treatments, so the observed reduction in 
satisfaction and smoking rate may be influenced by other factors than treatment. However, 
previous studies have demonstrated both pre-quit nicotine patch [133] and varenicline [57] 
caused reduction in satisfaction with smoking and smoking rate.  
 
6.7 Implications and conclusions 
The results suggested that pre-quit treatment use caused reductions in satisfaction with 
smoking and smoking rate. Satisfaction was associated with the reduction in smoking rate, 
although the mediation effect of satisfaction was weak. There might be other variables, such 
as craving and smoking dependence, with pre-quit treatment use that can be used to mediate 
smoking reduction. Our previous study has found there was reduction on craving with pre-
quit patch use in low smoking dependence smokers over the course of the pre-quit period 
[133]. Monitoring such reductions may prove a useful method of evaluating responsiveness 
to treatment and allow for tailoring of treatment. For example, future studies may want to test 
whether reduced satisfaction leads to reduced craving and dependence, which in turn predicts 
reductions in smoking rate. 
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Tobacco harm reduction strategies have made great advances in helping those who smoke to 
reduce the harm related to smoking. Smoking cessation has played an important role in the 
tobacco harm reduction. A variety of interventions have been applied to assist the 
achievement of cessation, however, the treatment outcomes have not been as efficient as 
expected. Studies have suggested that smokers were unable to obtain enough nicotine with 
existing regulator-approved NRT products, or struggled to quit completely, or found it 
difficult to sustain abstinence for a long period. Alternatively, smoking reduction with 
treatment has helped smokers to reduce smoking, either as an end itself or a step toward 
complete abstinence. Determination of how the use of treatment affects smoking reduction 
prior to complete abstinence has been useful, along with results on what the consequences of 
smoking reduction has been on the smoker. The objective of this thesis was to develop 
enhanced methods of examining harm exposure, specifically the development of a nicotine-
related biological marker in urine, and an assay to quantify the components of VNPs. 
Additionally, I planned to explore the drivers of reduction in the context of a quit attempt.  
 
A range of interventions used to assist smoking reduction. The new form of nicotine 
delivery products – VNPs – have caught the attention of smokers and these have become 
more and more popular in recent years. They have been considered as a tool, for reducing or 
quitting smoking, even though there were concerns on safety and unclear efficacy on 
cessation. Due to lack of product regulation, unlike NRT, the consistency of nicotine content 
in e-cigarettes was not clearly known. There are a variety of types of e-cigarette cartridges, 
such as fibrous material pad based cartridges and liquid cartridges. Because of the uncertain 
amount of nicotine and the varied form of cartridges, it may make the determination of the 
effectiveness of VNPs use in smoking reduction. A few assays have been designed to analyse 
the nicotine content in e-cigarette cartridges. However, these assays have been applied to 
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liquid cartridges, or refill solutions. A few assays have analysed the nicotine content in 
fibrous pad based cartridges, however, the internal standards used in those assays had 
different chemical properties from nicotine. Therefore, the nicotine content in these cartridges 
may not be accurately represented. An efficient and accurate assay was developed and 
applied to determine the nicotine content in e-cigarettes, which consisted of a fibrous pad in 
the cartridge (Study 1). As results in our laboratory and others have shown that even nicotine 
free labelled cartridges may contain nicotine [105]. It can be a potential concern if given 
these VNPs as a control feature in a smoking study. This assay has been particularly useful 
where blank cartridges are not available. In this assay, a known content of nicotine-d4 was 
used as a standard spiked onto the fibrous cartridge pad material, and then compared with the 
nicotine-d4 standard, using external standardisation to calculate the recovery of nicotine-d4 
from the pad. This overcame the limitation of previous studies that had minimal validation 
with respect to recovery of analyte from the cartridge pad [105, 131].  
 
With this well-established methodology, assay performance validation criteria, 
including accuracy and precision, LoD and LLoQ, freeze/thaw and bench top stability, were 
validated. The indication from this assay shows that there was good performance for 
determining the nicotine content in e-cigarette cartridges. In addition, the assay was applied 
to one brand of e-cigarettes, to determine the nicotine content and compare the variation 
between batches and within batches. This assay also showed that nicotine content did not 
match what was claimed on the label. Significant differences (~25%) were found between 
cartridges labelled and the actual content of nicotine in e-cigarette cartridges. This finding 
indicated that the information regarding the nicotine content found on the product package 
provided by manufacturers, may mislead customers and therefore the direct comparison with 
e-cigarettes is difficult. Knowing the nicotine content in e-cigarettes is of particular 
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importance when interpreting the outcomes of studies designed to evaluate the safety of e-
cigarettes and / or their usefulness for smoking cessation and / or smoking reduction; 
particularly given the rate at which new products are emerging. Future studies examining the 
effectiveness of VNPs as either smoking reduction or smoking cessation aids will be able to 
use our assay to accurately report the nicotine content of the products used. This assay also 
will be able to aid researchers and policy makers who try to compare results across studies 
using different devices.    
 
Apart from examining the treatment product itself, biological markers can be used to 
indicate the intake of nicotine and the exposure of smoking-related harm. The metabolites – 
NNAL and its glucuronides – are considered important biomarkers for NNK intake. 
Glucuronidation is an important NNK detoxification pathway. As discussed earlier, two 
isomers of NNAL-glucuronides, NNAL-N- and NNAL-O-glucuronide, are formed during the 
glucuronidation process. It is interesting to know whether the isomers of NNAL-glucuronides 
have potential importance to represent the NNK. Previous study indicated that liver 
microsomes from smokers (n=14) exhibited no significant difference in the levels of either 
NNAL-N-glucuronide or NNAL-O-glucuronide formation (not enantioselective), or in the 
ratio of NNAL-N-glucuronide/NNAL-O-glucuronide formation, as compared with liver 
microsomes from never smokers (n = 28) [181]. In addition, previous research has shown that 
(S)-NNAL and its glucuronides predominated in urine, with (S):(R)-ratios increased seven 
days after cessation. This indicated (S)-NNAL was retained in the body longer than (R)-
NNAL. (S)-NNAL is considered the major enantiomer involved in the slow elimination of 
NNAL [182]. In addition, (R)-NNAL-O-glucuronide is inactive as a lung tumorigenic in A/J 
mice contrasted to the potent lung tumorigenicity of (S)-NNAL and NNK [183]. Hence, for 
future research of NNK intake from tobacco, there is a strong rationale to measure (S)-NNAL 
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and (S)-NNAL-N-glucuronide in smokers’ urine. NNAL-N-glucuronides have been reported 
to contribute substantially to total combined NNAL-glucuronides. Therefore, free NNAL and 
NNAL-N-glucuronide are used as biomarkers of NNK intake from tobacco. To measure the 
levels of NNAL in smokers’ urine, SPE assay was employed to reduce the interference that 
had been found from urine matrix in previously reported studies [124, 141]. However, the 
sample preparation procedures were complicated and difficult to replicate. Hence, a simple 
and efficient assay was developed (Study 2) to measure NNAL levels in smokers’ urine while 
undergoing smoking reduction treatment.  
 
As mentioned above (in Chapter 4), the reported SPE methods have been complex, 
with multiple preparation steps, which involved different stationary phases and solvents. To 
replace SPE, in this thesis, new types of liquid-liquid extraction methods, such as DLLME 
and DLLME-SFO, were considered when applied for NNAL extraction. These new 
extraction methods have advantages compared with the traditional liquid-liquid extraction 
assay, including minimal extraction solvent consumption, short extraction time. Therefore, 
both DLLME and DLLME-SFO and along with an additional three assays (derivatisation of 
NNAL, SPE and liquid-liquid extraction assay) associated with UPLC-MS/MS were 
developed for determining NNAL levels in urine samples. Efficacy of these assays was 
verified with the recovery of NNAL from urine samples. The recovery of NNAL was 
calculated based on the NNAL-d3 concentration in urine samples and compared to a NNAL-
d3 standard, prepared to a concentration equivalent to recovery from the blank urine samples. 
 
With the DLLME, the extraction solvent is required to have a lower solubility but a 
higher density than water, and the disperser solvent was used to assist the dispersion of the 
extraction solvent into the aqueous phase. However, the low NNAL recovery, that was not 
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efficient, especially given the low biological levels, limited the application of this assay for 
NNAL extraction. Similarly, the DLLME-SFO assay was not suitable for NNAL extraction. 
With the DLLME-SFO assay, 1-undecanol was used as the extraction solvent. 1-Undecanol 
has a low melting point (11 °C), which solidifies at ambient temperature (20 to 25 °C). 1-
Undecanol also has less density than water, which would cause it to float above the aqueous 
phase, thereby making it easier for transferring the extract. However, the challenge with using 
1-undecanol was it became too difficult to evaporate it directly with nitrogen gas, as 1-
undecanol is highly lipophilic with a boiling point of 243°C. Even using other lipophilic and 
hydrophilic solvents to assist the evaporation process, 1-undecanol still could not be 
evaporated. Increasing the evaporation temperature (25, 32, and 45 °C) and the evaporation 
duration (15, 25 and 40 min) may have the potential to lose the analytes, either through 
chemical decomposition or evaporative loss. In addition, the UPLC column used in this study 
was narrower than the column used in previously reported studies. Thus, the UPLC column 
condition was not suitable for direct injection of 1-undecanol.  
 
SPE assay with simplified extraction procedures was developed. One extraction 
solvent (acetonitrile) and one type of SPE cartridge were used to extract NNAL from urine 
samples. However, the NNAL chromatogram signals were embedded with background 
signals due to the matrix interference from urine. Thus, this simplified SPE assay was also 
found to be not suitable for NNAL extraction in urine samples.  
 
As these three extraction assays were a failure for NNAL extraction, a liquid-liquid 
extraction assay was developed. The advantage of this assay is that NNAL can be accurately 
quantified with a single ethyl acetate extraction. The recovery of NNAL from urine samples 
(~65%) was greater than other assays (~25%) with this assay. The assay performance data 
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presented good accuracy results and precision values. Assay performance validated in blank 
urine met the bioanalytical quality control criteria [150]. The chromatogram also clearly 
presented a level of NNAL 45 pg/mL (at the lower range of NNAL samples) from a smoker’s 
urine sample. Hence, liquid-liquid extraction assay is a good option for NNAL analysis and 
does not require extensive solid phase extraction sample preparation. This simple and 
efficacy liquid-liquid assay can be practically applied to evaluate the reduction of smoking-
related harm exposure in future smoking study when use NNAL as a biological marker to 
determine harm exposure in smoking studies.  Importantly, such biological markers are more 
accurate measures of exposure than self-reported smoking rates (as smokers can vary the 
“intensity” with which they smoke individual cigarettes, and hence to some extent 
compensate for a reduced number of CPD).    
 
The validated liquid-liquid extraction assay was applied to smokers’ urine samples, 
which had been collected from current smokers who were participants in a larger smoking 
cessation study (Study 3). The results of free NNAL levels in smokers’ urine clearly 
indicated that there was a significant reduction following attempts by smokers to quit. This 
supports the use of NNAL as a biomarker of smoking-related exposure and harm reduction. 
In future smoking reduction studies, the impact of treatments on smoking reduction can be 
effectively evaluated by monitoring smoking behaviour, as well as by using biological 
markers – NNAL – to determine the actual harm exposure. Such designs will allow for a 
more accurate evaluation of the effectiveness of treatments in promoting smoking reduction. 
 
Furthermore, this liquid-liquid extraction assay provided the evidence of the 
limitation of enzymatic hydrolysis of NNAL-glucuronide for measuring the NNAL aglycone, 
which is not recommended. The ratio of NNAL-glucuronide to total NNAL was proposed as 
  Chapter 7	
	 103	
a potential biomarker [153] with rapid metabolism to the glucuronide inferring faster 
detoxification [154]. However, it was unclear what the ratio required would be with different 
findings between studies and ethnic groups [124, 126, 154, 155]. These reported methods 
were based on enzymatic cleavage of the NNAL-glucuronide to yield the aglycone and 
measure total NNAL after hydrolysis; this approach can lead to loss of accuracy and 
precision [156]. As we have shown, the NNAL-glucuronide measurement procedure 
(enzymatic hydrolysis approach to determine total levels) appears to be a major reason for the 
variability in the ratio of NNAL (free) to NNAL-glucuronide between individuals, but not the 
only reason. Variability could also be due to pharmacogenetic based differences in 
metabolism between individuals, differences in time between total cigarettes and last 
cigarette smoked, and differences in sample collection time relative to smoking pattern. Even 
for the glucuronides themselves, there is variability in NNAL-O-glucuronide and NNAL-N-
glucuronide formation between individuals, and hence different pharmacokinetic profiles. 
The determination of total (free + conjugated) NNAL requires a proper analytical assay 
validation. In this study, total (free + glucuronide) NNAL levels were measured with the 
similar hydrolysis approach by using β-glucuronidase enzyme to hydrolyse NNAL-
glucuronide conjugates to free NNAL aglycone. The results indicated that the ratio of total 
NNAL to free NNAL was below 1 for some urine samples in this sample population. And 
there was loss of NNAL aglycone from smokers’ urine samples following enzymatic 
hydrolysis. The loss of NNAL aglycone might be due to aglycone becoming unstable in 
hydrolytic conditions in the standard procedure, or because it binds non-specifically to the β-
glucuronidase or matrix [156]. NNAL-glucuronide measurement undertaken with standard 
enzymatic hydrolysis procedures is not reliable. Direct determination with using glucuronide 
standards would be highly recommended for future work. Our previous glucuronide study has 
indicated the direct determination could accurately measure the glucuronide levels in urine 
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samples [128]. The reason for not performing the direct analysis of NNAL-glucuronide was 
limited research time and costs in excess of the research budget. As discussed earlier, (S)-
NNAL and (S)-NNAL-N-glucuronide are the major enantiomers in smokers’ urine. The 
analytical assay (e.g. UPCL-MS/MS) can be applied to measure NNAL levels, specific to 
(S)-NNAL. In addition, the glucuronide standard approach to directly measure the NNAL-
glucuronide levels in human urine samples should be used to perform a proper validation of 
indirect methods, such as β-glucuronidase hydrolysis to measure total NNAL (free + 
glucuronide) or conjugated NNAL by difference (as used in the detoxification ratio). A very 
recent research study has used NNAL-N-glucuronide standards with using LC/MS method to 
directly determine the levels of NNAL-glucuronides in urine samples [184]. This study 
successfully measured different types of NNAL-glucuronide isomers, including NNAL-N-
glucuronides, (R)-NNAL-O-glucuronides and (S)-NNAL-glucuronide, in smokers’ urine 
samples. The study indicated the association of UDP enzyme genotypes and the capacity of 
detoxification against NNAL,  which may influence the cancer risk upon exposure to tobacco 
[184]. Utilisation of the biomarker assay to assess the urine samples of smokers is a 
potentially beneficial future strategy for smoking harm reduction. NNAL is a powerful 
carcinogenic biomarker from tobacco exposure. It is important to understand and monitor 
smoking reduction approaches with regard to exposures to tobacco-related harm, long-term 
follow-up of smoking reduction and / or cessation as well as to assess the risk of lung and 
other cancers. 
 
Apart from determining the measures of therapeutic product itself and biological 
markers of harm exposure, it is also essential to understand the mechanism of the treatments 
promoted smoking reduction and allow to tailor the treatment consequences. A clinical trial 
involving two treatments – nicotine patches and varenicline – used two weeks prior to a quit 
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attempt, was conducted to explore the effect of treatments on smoking reduction and 
satisfaction with smoking, and the mediation relationship between smoking rate and 
satisfaction with smoking (Study 4). The study results indicated that both pre-quit treatments 
promoted a significant reduction in both the satisfaction with smoking and daily smoking rate 
from baseline to the end of the pre-quit period. This reduction was not observed in 
participants with standard patch regimen. The observed reduction of daily smoking rate could 
be attributed to the reduction of satisfaction with smoking, although the mediation effect of 
satisfaction was relatively small. Satisfaction with smoking might be a plausible marker of 
treatment response, potentially allowing for better tailoring of mediation type, pre-quit 
treatment duration, or both. However, the relatively weak relationship between satisfaction 
and smoking reduction suggest that satisfaction may not be a viable method of evaluation 
responsiveness to treatment. There would be other variables of reduction with pre-quit 
treatments, such as craving and smoking dependency. Furthermore, we used the NNAL assay 
that we developed in Chapter 4 to determine the tobacco-related harm reduction observed in 
Study 4. This data was presented in Chapter 5. The biological data was not included in the 
Study 4 (Chapter 6) because we focused on presenting the effectiveness of pre-quit treatment 
on reduction of smoking rate and satisfaction with smoking. For future studies, examining the 
relationship between cravings, dependence on smoking, and measuring the levels of 
biological markers may prove to be useful in evaluating responsiveness to treatment, risk of 
harm, and allow for tailoring of treatment. 	
	
 
 
 
 
 
 
Chapter 8: Conclusion 
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Tobacco harm reduction aims to help reduce the morbidity and mortality of smoking related 
harm. Smoking cessation has been recommended as an effective strategy for tobacco harm 
reduction. More recently, smoking reduction is considered an alternate approach to reducing 
smoking harm exposure and may promote complete cessation. The reduction is quantified by 
measuring the constituents in nicotine products and measuring bioanalytical markers in 
biological fluid. The research purpose is to 1) develop improved measures of the constituents 
of medical nicotine products, particularly in VNPs; 2) develop measures of biological 
markers and apply these to assess smoking reduction; and 3) effectively use pre-quit 
treatments and accurately study smoking behaviour and its consequences. This thesis reported 
the development of assays for determining the nicotine content in new nicotine delivery 
products, as well as the development of an assay for measuring NNAL in smokers’ urine, all 
measures that assist exploration of the drive for smoking reduction with nicotine treatments.  
 
A variety of nicotine substitute treatments were used to assess the reduction, including 
new forms of nicotine delivery devices, known as VNPs. VNPs have increased the interest in 
helping to reduce cigarette smoking. To better measure more accurately the reduction for 
smokers while using VNPs, the constituents of VNPs must be clearly known before they can 
be used to measure the intake and exposure of smoking harm. In this thesis, an effective and 
accurate assay was developed to measure the nicotine content in the VNPs cartridges. This 
assay was important to determine the nicotine content in fibrous material pad based cartridges, 
especially as most existing assays have been designed to analyse nicotine content in liquid 
cartridges or refill solutions. In addition, this assay used deuterated nicotine, as an external 
standard, to quantify the nicotine content. This overcame the limitation of previous assays 
which included a standard with a different chemical property to nicotine. This analysis assay 
was successfully applied to determine the nicotine content in one brand of VNPs. The results 
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indicated a variation of actual nicotine content in the cartridge and to the content stated on the 
package label. VNP based products are currently unregulated and their market is rapidly 
evolving. These products vary in the types of delivery mechanisms used, and development of 
gold standard chromatographic methods to measure nicotine content need to be tailored to the 
particular device. VNP products have been developing rapidly, and methods to measure 
nicotine content have not kept pace, largely due to the fact there is no regulatory requirement 
for quality assurance of nicotine content. Accurate determination of nicotine content in VNP 
products, along with assay quality assurance is a fundamental requirement when assessing 
these products for harm and safety, and if they have any role in smoking reduction.  
 
Apart from knowing the constituents of nicotine products themselves, the biological 
markers were used as a determinant for the intake of nicotine and smoking-related harm 
aimed at smoking reduction. The biological marker – NNAL – provided the analytical 
evidence to support the outcomes of smoking reduction. In this thesis, an efficient and easy to 
approach measurement assay, was developed to determine NNAL levels in urine samples. 
The assay was successfully applied on participants currently involved in a smoking reduction 
study. In addition, there were advantages associated with this newly developed liquid-liquid 
extraction assay, especially combined with UPLC-MS/MS. To establish the accomplished 
methodology, different methods were designed and compared. It was also found that new 
types of extraction methods, DLLME and DLLME-SFO, were not suitable for NNAL 
determination. There were limitations with the capacity of the extraction solvent in the 
DLLME method and the issue with evaporating the extraction solvent in DLLME-SFO 
method. In addition, simplified SPE procedures were designed, but this resulted in 
chromatographic signals of analyte which were embedded with the background noise signals. 
Therefore, the urine matrices interference was not effectively reduced with the simplified 
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SPE procedures. In summary, the established liquid-liquid extraction assay coupled with 
UPLC-MS/MS was found to be more efficient for NNAL analysis when applying NNAL as 
biological markers to examine the actual smoking harm exposure in clinical smoking 
reduction studies.  
 
Apart from developing the assays for the measures of the constituents of nicotine 
products and the biological markers, a better understanding on the impact of reduction was 
also important. A clinical trial involving two treatments: nicotine patches and varenicline was 
conducted. This trial examined the effect of pre-quit treatments on smoking rate and 
satisfaction with smoking. The two treatments were applied two weeks prior to a target quit 
day (as pre-quit groups), and compared with a normal standard nicotine patch applied on the 
target quit day (as a control group). The study found that the satisfaction with smoking and 
smoking rate were significantly reduced during the pre-quit treatment period in the pre-quit 
treatment groups; the control group did not. Satisfaction was significantly associated with the 
reduction of smoking rate, although the mediation effect was relatively small. Satisfaction did 
not appear to be a viable method of evaluating responsiveness of treatment. Other variables, 
for example craving and dependence on smoking, may mediate the smoking reduction. In 
addition, based on the findings of the NNAL assay that we developed, there was a significant 
reduction in biological markers of harm after a quit attempt with using smoking treatments. 
For future studies, examining the relationship between cravings, dependence on smoking, and 
measuring the levels of biological markers may prove to be useful in evaluating 
responsiveness to treatment, risk of harm, and allow for tailoring of treatment.  
 
In summary, we know that there is no known safe level of smoking: every cigarette 
smoked increases an individual’s risk of tobacco-related disease. Tobacco-related harm 
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reduction strategies aim to assist people to reduce smoking. However, quantifying the risks 
and benefits of tobacco harm reduction, either at a socially or an individual level, is 
complicated, even assessing reduction itself is complicated as the exact harm associated with 
each cigarette is not consistent: it is a crude measure reduction by simply counting the 
number of CPD that an individual consumes.  
 
To better quantify the reduction, methods of measuring biological markers of tobacco 
exposure and the constituents of tobacco products were developed. However, no current 
measure was a perfect proxy for actual exposure and there were limitations of the exist 
methods of measuring. Hence, this thesis aims to develop improved measures of exposure – 
both in terms of measuring biological markers of actual exposure, and in terms of the 
constituents of products themselves – and to use these measures to studying smoking 
behaviour and its consequences. The analytical assays of biological markers measurement 
were developed and successfully applied on participants in the smoking reduction study. 
Overall, pharmacotherapy products used as a pre-quit treatment prior to the complete 
cessation introduced a significant reduction in satisfaction with smoking and cigarette 
consumption. The biological marker – NNAL – provided the analytical evidences to support 
the outcomes of smoking reduction. In addition, the developed assay for determination of 
nicotine content in medical nicotine products may provide the implications for further study 
of the nicotine products and application of these products for smoking reduction. 
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